Edgar Filing: CONMED CORP

As filed with the Securities and Exchange Commission on May 1, 2002
Registration No. 333-_____
================================================================================

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------

FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
-----------------
CONMED Corporation
(Exact name of registrant as specified in its charter)

New York 16-0977505
(State or other jurisdiction (I.R.S. employer
of incorporation or identification number)
organization)

525 French Road
Utica, New York 13502-5994
(315) 797-8375
(Address, including zip code, and telephone number,
including area code, of registrant's principal
executive offices)
Daniel S. Jonas
Vice President - Legal Affairs
and General Counsel
525 French Road
Utica, New York 13502-5994
(315) 797-8375
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
----------------------
Copies to:

Robert W. Downes Allan G. Sperling
Sullivan & Cromwell Cleary, Gottlieb, Steen & Hamilton
125 Broad Street One Liberty Plaza
New York, NY 10004 New York, NY 10006
(212) 558-4000 (212) 225-2000

Approximate date of commencement of proposed sale to the public: As soon
as practicable after the effective date of this Registration Statement.

-----------------------

If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box.[ ]
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with
dividend or interest reinvestment plans, check the following box. [ ]

If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.[ ] __________

If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration
statement for the same offering.[ ]
----------
If delivery of the prospectus is expected to be made pursuant to Rule
434, please check the following box.[ ]

----------

CALCULATION OF REGISTRATION FEE
=================================================================================================================

Proposed maximum Proposed maximum
Title of each class of securities Amount to be offering price aggregate Amount of
to be registered Registered per share(2) offering price(2) registration fee
------------------------------------------------------------------------------------------------------------------

Common Stock, par value $0.01 per share 3,450,000 $25.285 $87,233,250 $8,026
shares(1)
==================================================================================================================

(1) Includes 450,000 shares of Common Stock that the underwriters have the
option to purchase to cover over-allotments, if any.

(2) Estimated in accordance with Rule 457(c) under the Securities Act of 1933
solely for purposes of calculating the registration fee (based on the
average of the high and low prices of CONMED Corporation common stock as
reported in the Nasdaq National Market on April 24, 2002).

The Registrant hereby amends this Registration Statement on such date or dates
as may be necessary to delay its effective date until the Registrant shall file
a further amendment which specifically states that this Registration Statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until this Registration Statement shall become
effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section 8(a), may determine.
================================================================================

THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE MAY
NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN
OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE
SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.

SUBJECT TO COMPLETION, DATED MAY 1, 2002

PROSPECTUS
[CONMED Logo]

3,000,000 Shares

CONMED Corporation

Common Stock
$ _____ per share

---------

We are selling 3,000,000 shares of our common stock in this offering.
We have granted the underwriters an option to purchase up to 450,000 additional
shares of our common stock to cover any over-allotments.

Our common stock is quoted on the Nasdaq National Market under the
symbol "CNMD". The last reported sale price of our common stock on the Nasdaq
National Market on April 29, 2002, was $25.49 per share.

------------

Investing in our common stock involves risks. See "Risk Factors"
beginning on page 7.

Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.

-------------

Per share Total

---------------- ---------------
Public offering price $ $
Underwriting discount $ $
Proceeds to CONMED (before expenses) $ $

The underwriters expect to deliver the shares to purchasers on or about
_________ __, 2002.

-------------

Salomon Smith Barney
UBS Warburg
Needham & Company, Inc.
First Albany Corporation

________ __, 2002

[Insert Pictures of Products]

TABLE OF CONTENTS

Page
Summary....................................................................................1
Risk Factors...............................................................................7
Cautionary Statement Concerning Forward-Looking Statements................................13
Price Range of Our Common Stock...........................................................14
Dividend Policy...........................................................................14
Use of Proceeds...........................................................................15
Capitalization............................................................................16
Selected Financial Data...................................................................17
Management's Discussion and Analysis of Financial Condition and Results of Operations.....20
Business..................................................................................30
Management................................................................................43
Description of Capital Stock..............................................................45
Shares Eligible for Future Sale...........................................................46
Underwriting..............................................................................48
Validity of Common Stock..................................................................50
Experts...................................................................................50
Where You Can Find More Information.......................................................50
Index to Financial Statements............................................................F-1

--------------------------

You should rely only in the information contained in or incorporated by
reference in this prospectus. We have not authorized anyone to provide you with
different information. We are not making an offer of these securities in any
state or other jurisdiction where the offer is not permitted. You should not
assume that the information contained in this prospectus is accurate as of any
date other than the date on the front of this prospectus.

SUMMARY

The following summary is qualified in its entirety by the more detailed
information and financial statements appearing elsewhere in this prospectus or
incorporated by reference herein. An investment in the Common Stock involves
significant risks. See "Risk Factors."

CONMED Corporation

CONMED Corporation is a medical technology company specializing in
instruments, implants and video equipment for arthroscopic sports medicine, and
powered surgical instruments, such as drills and saws, for orthopedic, ENT,
neuro-surgery and other surgical specialties. We are also a leading developer,
manufacturer and supplier of advanced surgical devices, including radio
frequency, or RF, electrosurgery systems used routinely to cut and cauterize
tissue in nearly all types of surgical procedures worldwide and endoscopy
products such as trocars, clip appliers, scissors and surgical staplers. We
also manufacture and sell a full line of ECG electrodes for heart monitoring
and other patient care products.

The following table sets forth the percentage of net sales for each
category of our products for 1999, 2000 and 2001:

Year Ended December 31,
--------------------------------------
1999 2000 2001
---------- ------------- -----------
Arthroscopy........................... 38% 36% 36%
Powered surgical instruments.......... 23 29 27
Electrosurgery........................ 17 16 16
Patient Care.......................... 21 17 16
Endoscopy............................. 1 2 5
---------- ------------- -----------
Total............................ 100% 100% 100%
========== ============= ===========
Net sales (in thousands).............. $376,226 $395,873 $428,722
========== ============= ===========

Our products are used in a variety of clinical settings such as
operating rooms, surgery centers, physicians' offices and critical care areas of
hospitals. We employ a razor/razor blade business model whereby we sell capital
equipment and the associated single-use disposable products. During 2001, we
derived approximately 75% of our revenues from single-use disposable products
and the remainder from capital equipment. We believe the sale of disposable
products provides a recurring revenue stream that helps insulate us from
temporary market downturns.

We have used strategic business acquisitions to broaden our product
offerings, to increase our market share in certain product lines and to realize
economies of scale. Since 1997, we have completed six significant business
acquisitions. The completed acquisitions, together with internal growth, have
resulted in a compound annual growth rate in net sales of 32% between 1997 and
2001.

Industry

The growth in the markets for our products is primarily driven by:

Continued Pressure to Reduce Health Care Costs. In response to rising
health care costs, managed care companies and other third-party payers have
placed pressures on health care providers to reduce costs. In turn, health care
providers are increasingly purchasing single-use, disposable products, which
reduce the costs associated with sterilizing surgical instruments and products
following surgery.

Increased Global Medical Spending. We believe that foreign markets
offer growth opportunities for our products. We currently distribute our
products through our own sales subsidiaries or through local dealers in over 100
foreign countries. International sales represented approximately 29% of total
sales in 2001.

Competitive Strengths

We believe that we have a top two or three market share position in
each of our five key product areas and have established our position as a market
leader by capitalizing on the following competitive strengths:

o Strong Brand Recognition. Our products are sold under leading brand
names, including CONMED(R), Linvatec(R), and Hall Surgical(R). These
brand names are well recognized by physicians for quality and service,
and we believe that brand recognition helps drive demand for our
products.

o Successful Integration of Acquisitions. Since 1997, we have completed
six acquisitions, including the 1997 acquisition of Linvatec
Corporation which more than doubled our size. Our management team,
which averages more than 15 years of experience in the health care
industry, has demonstrated a historical ability to identify
complementary acquisitions and to integrate acquired companies into
our operations.

o Extensive Marketing and Distribution Infrastructure. We market our
products domestically through our sales force consisting of
approximately 210 employee sales representatives and an additional 90
sales professionals employed by eight non-stocking sales agent groups,
seven of which are exclusive. Additionally, we have an international
presence through sales subsidiaries and branches located in key
international markets.The size and coverage of our distribution
infrastructure assists in driving our sales.

Business Strategy

Our business strategy is to continue to strengthen our position as a
market leader in our key product areas. The elements of our strategy include:

-2-

o Introduce New Products and Product Enhancements. We will continue to
pursue organic growth by developing new products and enhancing
existing products to respond to customer needs and preferences.

o Realize Manufacturing and Operating Efficiencies. We will continue to
review opportunities for consolidating product lines and streamlining
production. We believe our vertically integrated manufacturing
processes can produce further opportunities to reduce overhead and to
increase operating efficiencies and capacity utilization.

o Maintain Strong International Sales Growth. We intend to maintain our
international sales growth and increase our penetration into
international markets by utilizing our relationships with foreign
surgeons, hospitals and third-party payers, as well as foreign
distributors.

Recent Development

Purchase and Cancellation of Warrant Issued to Bristol-Myers Squibb. In
1997, in connection with the acquisition of Linvatec, we issued to Bristol-Myers
Squibb Company a warrant exercisable in whole or in part for up to 1,500,000
shares of our common stock at a price of $22.82 per share. On April 30, 2002, we
agreed to purchase the warrant for $2 million in cash and upon its repurchase,
we intend to cancel it.

-3-

The Offering

Common stock offered by us.......... 3,000,000 shares

Common stock outstanding
after this offering............ 28,549,358 shares

Use of proceeds..................... We will use the estimated net proceeds of
approximately $___ million that we will
receive from this offering for the
repayment of bank debt. See "Use of
Proceeds."

Nasdaq National Market symbol....... CNMD

The number of shares of common stock to be outstanding after this
offering is based upon 25,549,358 shares of common stock that were outstanding
on March 29, 2002 and does not include the following:

o 3,440,829 shares of common stock issuable based upon the
exercise of outstanding stock options as of March 29, 2002
under our stock option plans, of which 1,719,932 shares were
exercisable.

o 450,000 shares of common stock issuable in this offering to
the underwriters pursuant to an over-allotment option.

Our executive offices are located at 525 French Road, Utica, New York
13502-5994. Our telephone number is (315) 797-8375 and our internet address is
www.conmed.com. The information contained on our website is not part of this
prospectus.

-4-

Summary Financial Data

The information below sets forth summary financial data as of and for
each of the three years in the period ended December 31, 2001 and the three
months ended March 31, 2001 and 2002. The data for the three years in the period
ended December 31, 2001 and as of December 31, 2000 and 2001 has been derived
from and should be read in conjunction with our consolidated financial
statements, including the notes thereto, included in the prospectus beginning on
page F-1, and "Management's Discussion and Analysis of Financial Condition and
Results of Operations" herein. The information as of December 31, 1999 has been
derived from our audited financial statements not incorporated by reference or
included herein. The summary financial data for the three months ended March 31,
2001 and 2002 are unaudited but, in the opinion of management, reflect all
adjustments (comprising only normal recurring accruals) necessary for a fair
presentation of our consolidated operating results and financial position for
such interim periods. Results for interim periods are not necessarily indicative
of results for the full year or for any other period. We have never paid any
cash dividends.

Three Months
Year Ended December 31, Ended March 31,
----------------------- ---------------
1999 2000 2001 2001 2002
---- ---- ---- ---- ----
(in thousands, except per share and share data)
(unaudited)

Statement of Income Data (1):
Net sales .................................. $376,226 $395,873 $428,722 $105,909 $113,205
Cost of sales (2) .......................... 178,480 188,223 204,374 49,674 54,104
Selling and administrative expense (3) (4) . 110,842 128,316 140,560 34,829 34,468
Research and development expense ........... 12,108 14,870 14,830 3,696 3,824
------ ------ ------ ----- -----

Income from operations .................. 74,796 64,464 68,958 17,710 20,809
Interest expense, net ...................... 32,360 34,286 30,824 8,331 6,628
------ ------ ------ ----- -----
Income before income taxes
and extraordinary item ............. 42,436 30,178 38,134 9,379 14,181
Provision for income taxes ................. 15,277 10,864 13,728 3,376 5,105
------ ------ ------ ----- -----
Net income ............................. $ 27,159 $ 19,314 $ 24,406 $ 6,003 $ 9,076
======== ======== ======== ======== ========

Earnings Per Share:
Basic ...................................... $ 1.19 $ 0.84 $ 1.02 $ 0.26 $ 0.36
-------- -------- -------- -------- --------
Diluted .................................... $ 1.17 $ 0.83 $ 1.00 $ 0.26 $ 0.35
======== ======== ======== ======== ========

Weighted Average Number of Common Shares Used In Calculating:

Basic earnings per share ................... 22,862 22,967 24,045 23,057 25,397
======== ======== ======== ======== ========
Diluted earnings per share ................. 23,145 23,271 24,401 23,307 25,969
======== ======== ======== ======== ========

Other Financial Data:
Depreciation and amortization $ 26,291 $ 29,487 $ 30,148 $ 7,566 $ 5,403
Capital expenditures ....................... 9,352 14,050 14,443 3,867 3,208

(footnotes on following page)

-5-

As of As of
December 31, March 31,
------------------------- ---------
1999 2000 2001 2002
---- ---- ---- ----
Balance Sheet Data (in thousands)
(unaudited)

Cash and cash equivalents ...................$ 3,747 $ 3,470 $ 1,402 $ 2,634
Working capital ............................. 109,526 113,755 44,712 47,434
Total assets ................................ 662,161 679,571 701,608 706,950
Long-term debt (including current portion) .. 394,669 378,748 335,929 325,991
Total shareholders' equity .................. 211,261 230,603 283,634 295,211

-------------

(1) Includes, based on the purchase method of accounting, the results of (i)
the powered instrument product line acquired from 3M Company, from August
1999; and (ii) the minimally invasive surgical product lines acquired from
Imagyn Medical Technologies, Inc. in November 2000 and July 2001; in each
such case from the date of acquisition.

(2) Includes for 1999, $1,600,000 of incremental expense related to the excess
of the fair value at the acquisition date over the cost to produce
inventory related to the powered instrument product line acquired from 3M;
and includes for 2001, $1,567,000 of transition expenses related to the
July 2001 acquisition from Imagyn.

(3) Included in selling and administrative expense for 1999 is a $1,256,000
benefit related to a previously recorded litigation accrual which was
settled on favorable terms. Included in selling and administrative expense
for 2000 is a severance charge of $1,509,000 related to the restructuring
of our arthroscopy sales force.

(4) Effective January 1, 2002, the provisions of SAFS 142 were adopted
relative to the cessation of amortization for goodwill and certain
intangibles. Had we accounted for goodwill and certain intangibles in
accordance with SAFS 142 for all periods presented, net income would have
been $32,227 in 1999, $24,969 in 2000, $30,061 in 2001 and $7,416 in the
three months ended March 31, 2001.

-6-

RISK FACTORS

An investment in our common stock involves a high degree of risk. You
should carefully consider the following factors, in addition to the other
information contained in this prospectus, in deciding whether to invest in our
common stock. This prospectus and documents incorporated by reference herein
contain forward-looking statements that involve risks and uncertainties. Our
actual results may differ significantly from the results discussed in the
forward-looking statements. See "Cautionary Statement Concerning Forward-Looking
Statements" below. Factors that might cause such differences include those
discussed below.

Our financial performance is subject to the risk of business
acquisitions, including the effects of increased borrowing and the integration
of businesses. A key element of our business strategy has been to expand through
acquisitions and we may seek to pursue additional acquisitions in the future.
Our success is dependent in part upon our ability to integrate acquired
companies or product lines into our existing operations. We may not have
sufficient management and other resources to accomplish the integration of our
past and future acquisitions, and implementing our acquisition strategy may
strain our relationship with customers, suppliers, distributors, manufacturing
personnel or others. There can be no assurance that we will be able to identify
and make acquisitions on acceptable terms or that we will be able to obtain
financing for such acquisitions on acceptable terms. In addition, while we are
generally entitled to customary indemnification from sellers of businesses for
any difficulties that may have arisen prior to our acquisition of each business,
acquisitions may involve exposure to unknown liabilities and the amount and time
for claiming under these indemnification provisions is often limited. As a
result, our financial performance is now and will continue to be subject to
various risks associated with the acquisition of businesses, including the
financial effects associated with any increased borrowing required to fund such
acquisitions or with the integration of such businesses.

Failure to comply with regulatory requirements could result in recalls,
fines or materially adverse implications. All of our products are classified as
medical devices subject to regulation by the Food and Drug Administration. As a
manufacturer of medical devices, our manufacturing processes and facilities are
subject to on-site inspection and continuing review by the FDA for compliance
with the Quality System Regulations. Manufacturing and sales of our products
outside the United States are also subject to foreign regulatory requirements
that vary from country to country. The time required to obtain approvals from
foreign countries may be longer or shorter than that required for FDA approval,
and requirements for foreign approvals may differ from FDA requirements. Failure
to comply with applicable domestic and/or foreign requirements can result in:

o fines or other enforcement actions;

o recall or seizure of products;

o total or partial suspension of production;

o withdrawal of existing product approvals or clearances;

o refusal to approve or clear new applications or notices;

o increased quality control costs; or

o criminal prosecution.

The failure to comply with Quality System Regulations and applicable
foreign regulations could have a material adverse effect on our business,
financial condition or results of operations.

-7-

If we are not able to manufacture products in compliance with
regulatory standards, we may decide to cease manufacture of those products and
may be subject to product recall. In addition to the Quality System Regulations,
many of our products are also subject to industry-set standards. We may not be
able to comply with these regulations and standards due to deficiencies in
component parts or our manufacturing processes. If we are not able to comply
with the Quality System Regulations or industry-set standards, we may not be
able to fill customer orders and we may decide to cease production of
non-compliant products. Failure to produce products could affect our profit
margins and could lead to loss of customers.

Our products are subject to product recall and product recalls have
been made in the past. Although no recall has had a material adverse effect on
our business, financial condition or results of operations, we cannot assure you
that regulatory issues will not have a material adverse effect in the future or
that product recall will not harm our reputation and our relationships with our
customers.

The highly competitive market for our products may create adverse
pricing pressures. The market for our products is highly competitive and our
customers have numerous alternatives of supply. Many of our competitors offer a
range of products in areas other than those in which we compete, which may make
such competitors more attractive to surgeons, hospitals, group purchasing
organizations and others. In addition, many of our competitors are larger and
have greater financial resources than we do and offer a range of products
broader than our products. Competitive pricing pressures or the introduction of
new products by our competitors could have an adverse effect on our revenues.
Because our customers are not bound by long-term supply arrangements with us, we
may not be able to shift our production to other products following a loss of
customers to our competitors, leading to an accompanying adverse effect on our
profitability. See "Business -- Competition" for a further discussion of these
competitive forces.

Factors that could lead our customers to choose products offered by our
competitors include:

o changes in surgeon preferences;

o increases or decreases in health care spending related to
medical devices;

o our inability to furnish products to them, such as a result of
product recall or back-order;

o the introduction by competitors of new products or new
features to existing products;

o the introduction by competitors of alternative surgical
technology; and

o advances in surgical procedures and discoveries or
developments in the health care industry.

Cost reduction efforts in the health care industry could put pressures
on our prices and margins. In recent years, the health care industry has
undergone significant change driven by various efforts to reduce costs,
including efforts at national health care reform, trends toward managed care,
cuts in Medicare, consolidation of health care distribution companies and
collective purchasing arrangements by group purchasing organizations, or GPOs,
and integrated health networks, or IHNs. Demand and prices for our products may
be adversely affected by these trends.

-8-

We may not be able to keep pace with technological change or to
successfully develop new products with wide market acceptance, which could cause
us to lose business to competitors. The market for our products is characterized
by rapidly changing technology. Our future financial performance will in part be
dependent on our ability to develop and manufacture new products on a
cost-effective basis, to introduce them to the market on a timely basis, and to
have them accepted by surgeons.

We may not be able to keep pace with technology or to develop viable
new products. Factors which could cause delay in releasing new products or even
cancellation of our plans to produce and market these new products include:

o research and development delays;

o delays in securing regulatory approvals; or

o changes in the competitive landscape, including the emergence
of alternative products or solutions which reduce or eliminate
the markets for pending products.

Our new products may fail to achieve expected levels of market
acceptance. Any new products we launch may fail to achieve market acceptance.
The degree of market acceptance of any of our products will depend on a number
of factors, including:

o our ability to develop and introduce new products and product
enhancements in the time frames we currently estimate;

o our ability to successfully implement new technologies;

o the market's readiness to accept new products, such as our
PowerPro(R)Battery System;

o having adequate financial and technological resources for
future product development and promotion;

o the efficacy of our products; and

o the prices of our products compared to the prices of our
competitors' products.

If our new products do not achieve market acceptance, we may be unable
to recoup our investments and may lose business to competitors.

In addition, some of the companies with which we now compete or may
compete in the future have or may have more extensive research, marketing and
manufacturing capabilities and significantly greater technical and personnel
resources than we do, and may be better positioned to continue to improve their
technology in order to compete in an evolving industry. See
"Business--Competition" for a further discussion of these competitive forces.

Our credit agreement contains covenants that may limit our flexibility
or prevent us from taking actions. Our credit agreement contains, and future
credit facilities are expected to contain, certain restrictive covenants which
will affect, and in many respects significantly limit or prohibit, among other
things, our ability to:

o incur indebtedness;

o make prepayments of certain indebtedness;

-9-

o make investments;

o engage in transactions with affiliates;

o pay dividends;

o sell assets; and

o pursue acquisitions.

These covenants may prevent us from pursuing acquisitions,
significantly limit our operating and financial flexibility and limit our
ability to respond to changes in our business or competitive activities. Our
ability to comply with such provisions may be affected by events beyond our
control. In the event of any default under our credit agreement, the credit
agreement lenders could elect to declare all amounts borrowed under our credit
agreement, together with accrued interest, to be due and payable. If we were
unable to repay such borrowings, the credit agreement lenders could proceed
against the collateral securing the credit agreement, which consists of
substantially all of our property and assets, except for our accounts receivable
and related rights which are sold in connection with the accounts receivable
sales agreement. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations--Liquidity and Capital Resources" for a
discussion of the accounts receivable sales agreement.

Our substantial leverage and debt service requirements may force us to
adopt alternative business strategies. We have indebtedness that is substantial
in relation to our shareholders' equity, as well as interest and debt service
requirements that are significant compared to our cash flow from operations. On
a pro forma basis, after giving effect to the application of the proceeds of
this offering, as of March 31, 2002, we would have had $_____ million of debt
outstanding, representing ___% of total capitalization, and which does not
include the $40 million of receivables sold to a conduit purchaser under the
accounts receivable sales agreement described below under "Management's
Discussion and Analysis of Financial Condition and Results of
Operations--Liquidity and Capital Resources", the proceeds of which were used to
repay indebtedness.

The degree to which we are leveraged could have important consequences
to investors, including but not limited to the following:

o a substantial portion of our cash flow from operations must be
dedicated to debt service and will not be available for
operations, capital expenditures, acquisitions, dividends and
other purposes;

o our ability to renegotiate our revolving credit facility and
obtain additional financing in the future for working capital,
capital expenditures, acquisitions or general corporate
purposes may be limited or impaired, or may be at higher
interest rates;

o we may be at a competitive disadvantage when compared to
competitors that are less leveraged;

o we may be hindered in our ability to adjust rapidly to market
conditions;

o our degree of leverage could make us more vulnerable in the
event of a downturn in general economic conditions or other
adverse circumstances applicable to us; and

-10-

o our interest expense could increase if interest rates in
general increase because some of our borrowings, including our
borrowings under our credit agreement, are and will continue
to be at variable rates of interest.

We may not be able to generate sufficient cash to service our
indebtedness, which could require us to reduce our expenditures, sell assets,
restructure our indebtedness or seek additional equity capital. Our ability to
satisfy our obligations will depend upon our future operating performance, which
will be affected by prevailing economic conditions and financial, business and
other factors, many of which are beyond our control. We may not have sufficient
cash flow available to enable us to meet our obligations. If we are unable to
service our indebtedness, we will be forced to adopt an alternative strategy
that may include actions such as foregoing acquisitions, reducing or delaying
capital expenditures, selling assets, restructuring or refinancing our
indebtedness or seeking additional equity capital. We can not assure you that
any of these strategies could be implemented on terms acceptable to us, if at
all. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations - Liquidity and Capital Resources" for a discussion of our
indebtedness and its implications.

We may be unable to continue to sell our accounts receivable, which
could require us to seek alternative sources of financing. Under our receivables
agreement, there are certain statistical ratios which must be maintained
relating to the pool of receivables in order for us to continue selling to the
conduit purchaser and the conduit purchaser can cease its purchase of our
receivables. These ratios relate to sales dilution and losses on accounts
receivable. If new accounts receivable arising in the normal course of business
do not qualify for sale or the conduit purchaser otherwise ceases its purchase
of our receivables, we would need to access alternate sources of working
capital, which could be more expensive or difficult to obtain.

We may be unable to successfully renegotiate our credit facility on
terms we deem acceptable. Our $100 million revolving credit facility terminates
on December 31, 2002. We are currently negotiating with our bank group to extend
the revolving credit facility, or in the alternative, to renegotiate our entire
senior credit facility. We may be unable to obtain credit arrangements on terms
we deem acceptable. If we are unable to successfully negotiate a new senior
credit arrangement that provides sufficient capital for our business, we could
be forced to sell assets, alter our business strategy or obtain alternative
sources of financing.

The loss or invalidity of our patents may reduce our competitive
advantage. Much of the technology used in the markets in which we compete is
covered by patents. We have numerous U.S. patents and corresponding foreign
patents on products expiring at various dates from 2002 through 2019 and have
additional patent applications pending. See "Business -- Research and
Development Activities" for a further description of our patents. The loss of
our patents could reduce the value of the related products and any related
competitive advantage. Competitors may also be able to design around our patents
and to compete effectively with our products. Also, our competitors may allege
that our products infringe their patents, leading to voluntary or involuntary
loss of sales from those products. In addition, the cost to prosecute
infringements of our patents or the cost to defend our products against patent
infringement actions by others could be substantial. We cannot assure you that:

o pending patent applications will result in issued patents,

o patents issued to or licensed by us will not be challenged by
competitors,

o our patents will be found to be valid or sufficiently broad to
protect our technology or provide us with a competitive
advantage, or

-11-

o we will be successful in defending against pending or future
patent infringement claims asserted against our products.

Ordering patterns of our customers may change resulting in reductions
in sales. Our hospital and surgery center customers purchase our products in
quantities sufficient to meet their anticipated demand. Likewise, our
health care distributor customers purchase our products for ultimate resale to
health care providers in quantities sufficient to meet the anticipated
requirements of the distributors' customers. Should inventories of our products
owned by our hospital, surgery center and distributor customers grow to levels
higher than their requirements, our customers may reduce the ordering of
products from us. This could cause a reduction in our sales in a financial
accounting period.

Our significant international operations subject us to risks associated
with operating in foreign countries. A portion of our operations are conducted
outside the United States. About 29% of our 2001 net sales constituted foreign
sales. As a result of our international operations, we are subject to risks
associated with operating in foreign countries, including:

o devaluations and fluctuations in currency exchange rates;

o imposition of limitations on conversions of foreign currencies
into dollars or remittance of dividends and other payments by
foreign subsidiaries;

o imposition or increase of withholding and other taxes on
remittances and other payments by foreign subsidiaries;

o trade barriers;

o political risks, including political instability;

o reliance on third parties to distribute our products;

o hyperinflation in certain foreign countries; and

o imposition or increase of investment and other restrictions by
foreign governments.

We cannot assure you that such risks will not have a material adverse
effect on our business and results of operations.

We can be sued for producing defective products and our insurance
coverage may be insufficient to cover the nature and amount of any product
liability claims. The nature of our products as medical devices and today's
litigious environment should be regarded as potential risks that could
significantly and adversely affect our financial condition and results of
operations. The insurance we maintain to protect against claims associated with
the use of our products may not adequately cover the amount or nature of any
claim asserted against us and we are exposed to the risk that our claims may be
excluded and that our insurers may become insolvent. See "Item 3: Legal
Proceedings" in our Form 10-K for a further discussion of the risk of product
liability actions and our insurance coverage.

-12-

CAUTIONARY STATEMENT CONCERNING
FORWARD-LOOKING STATEMENTS

Forward-Looking Statements Made in this Prospectus

In this prospectus, we make forward-looking statements about our
financial condition, results of operations and business. Forward-looking
statements are statements made by us concerning events that may or may not occur
in the future. These statements may be made directly in this document or may be
"incorporated by reference" from other documents. You can find many of these
statements by looking for words like "believes," "expects," "anticipates,"
"estimates" or similar expressions.

Forward-Looking Statements are not Guarantees of Future Performance

Forward-looking statements involve known and unknown risks,
uncertainties and other factors, including those that may cause our actual
results, performance or achievements, or industry results, to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include those
identified under "Risk Factors" above and those set forth elsewhere and
incorporated by reference in this prospectus, among others, including the
following:

o general economic and business conditions;

o changes in customer preferences;

o changes in technology;

o the introduction of new products;

o changes in business strategy;

o the possibility that United States or foreign regulatory and/or
administrative agencies might initiate enforcement actions against us
or our distributors;

o quality of our management and business abilities and the judgment of
our personnel; and

o the availability, terms and deployment of capital.

See "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and "Business" below for a further discussion of these
factors. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. We do not undertake any
obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date of this prospectus or to
reflect the occurrence of unanticipated events.

-13-

PRICE RANGE OF OUR COMMON STOCK

Our common stock, par value $.01 per share, is traded on the Nasdaq
National Market under the symbol "CNMD". At March 29, 2002, there were 1,213
registered holders of our common stock and approximately 6,100 accounts held in
"street name."

The following table shows certain high-low last sales prices for our
common stock, as reported by the Nasdaq National Market. These sales prices have
been adjusted for a three-for-two split of our common stock effected in the form
of a common stock dividend and paid on September 7, 2001 to shareholders of
record on August 21, 2001.

Common Stock Price
------------------------------
Year Ended December 31, 2000: High Low
--------------- --------------

First Quarter............................. $20.50 $15.04
Second Quarter............................ 18.37 15.75
Third Quarter............................. 17.41 8.08
Fourth Quarter............................ 12.04 8.62

------------------------------
Year Ended December 31, 2001: High Low
--------------- --------------
First Quarter............................. $15.92 $10.83
Second Quarter............................ 18.00 13.08
Third Quarter............................. 21.21 15.73
Fourth Quarter............................ 21.01 16.53

------------------------------
Year Ended December 31, 2002: High Low
--------------- --------------
First Quarter............................. $25.00 $19.29
Second Quarter (through April 29, 2002)... $26.08 $24.11

On April 29, 2002, the last sale price for the common stock on the
Nasdaq National Market was $25.49.

DIVIDEND POLICY

We have never paid cash dividends on our common stock. Our board of
directors presently intends to retain future earnings to finance the development
of our business and does not intend to declare cash dividends. Should this
policy change, the declaration of dividends will be determined by our board in
light of conditions then existing, including our financial requirements and
condition and the limitation on the declaration and payment of cash dividends
contained in debt agreements.

-14-

USE OF PROCEEDS

The net proceeds from this offering, after payment of our fees and
expenses incurred in connection with this offering, are estimated to be
approximately $_______ million (assuming the underwriters' over-allotment option
is not exercised). We will use the net proceeds from this offering to repay
outstanding debt under our credit agreement.

The borrowings under our credit agreement, of which $172.8 million was
outstanding as of March 31, 2002, include a term portion that bears interest at
a weighted average of LIBOR plus 2.13% (4.20% at March 31, 2002) and a revolving
portion that bears interest at LIBOR plus 1.50% (3.70% at March 31, 2002).

-15-

CAPITALIZATION

The following table sets forth our consolidated capitalization as of
March 31, 2002, and as adjusted to give pro forma effect to our sale of
3,000,000 shares of our common stock offered hereby at an assumed offering price
of $__ per share and the application of the net proceeds therefrom as described
under "Use of Proceeds":

March 31, 2002
-----------------------------
Actual As Adjusted
---------- --------------
(in thousands)

Current portion of long-term debt(1) .................................... $ 73,914 $ 73,914

Long-term debt (less current portion)(1) ................................ $ 252,077 $
Shareholders' equity:
Preferred stock, par value $.01 per share;
authorized 500,000 shares; none outstanding ............... - -
Common stock, par value $.01 per share; authorized 100,000,000
shares; outstanding 25,549,358 shares actual and 28,549,358
shares as adjusted ........................................ 255 285
Paid-in capital ................................................ 162,740
Retained earnings .............................................. 137,316 137,316
Accumulated and other comprehensive loss ....................... (4,681) (4,681)
Less 37,500 shares of common stock
in treasury, at cost ...................................... (419) (419)
--------- ---------
Total shareholders' equity ................................ 295,211
--------- ---------
Total capitalization .................................. $ 547,288 $
========= =========

-----------------
(1) Because the revolving commitment under our credit agreement terminates
on December 31, 2002, the entire amount borrowed under our revolver is
classified as short term.

-16-

SELECTED FINANCIAL DATA

The information below sets forth selected financial data as of and for
each of the five years in the period ended December 31, 2001 and the three
months ended March 31, 2001 and 2002. The data for the three years in the period
ended December 31, 2001 and as of December 31, 2000 and 2001 has been derived
from and should be read in conjunction with our consolidated financial
statements, including the notes thereto, included in this prospectus beginning
on page F-1, and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" herein. The information for the years ended December
31, 1997 and 1998 and as of December 31, 1997, 1998 and 1999 has been derived
from our audited financial statements not incorporated by reference or included
herein. The selected financial data for the three months ended March 31, 2001
and 2002 are unaudited but, in the opinion of management, reflect all
adjustments (comprising only normal recurring accruals) necessary for a fair
presentation of our consolidated operating results and financial position for
such interim periods. Results for interim periods are not necessarily indicative
of results for the full year or for any other period. We have never paid any
cash dividends.

Three Months Ended
Year Ended December 31, March 31,
--------------------------------------------------------- ------------------
1997 1998 1999 2000 2001 2001 2002
---- ---- ---- ---- ---- ---- ----
(in thousands, except per share and share data)
(unaudited)
Statements of Income (Loss)
Data (1):

Net sales..................... $139,632 $339,270 $376,226 $395,873 $428,722 $105,909 $113,205
Cost of sales (2)............ 74,220 169,599 178,480 188,223 204,374 49,674 54,104
Selling and administrative
expense (3) (4)............ 36,661 96,475 110,842 128,316 140,560 34,829 34,468
Research and development
expense.................... 3,037 12,029 12,108 14,870 14,830 3,696 3,824
Unusual items (3)............. 37,242 - - - - - -
-------- -------- -------- ------- ------- ------- -------
Income (loss) from
operations.............. (11,528) 61,167 74,796 64,464 68,958 17,710 20,809
Interest income (expense), net 823 (30,891) (32,360) (34,286 ) (30,824) (8,331) (6,628)
-------- -------- -------- ------- ------- ------- -------
Income (loss) before
income taxes and
extraordinary item..... (10,705) 30,276 42,436 30,178 38,134 9,379 14,181
Provision (benefit) for
income taxes............... (3,640) 10,899 15,277 10,864 13,728 3,376 5,105
-------- -------- -------- ------- ------- ------- -------
Income (loss) before
extraordinary item...... (7,065) 19,377 27,159 19,314 24,406 6,003 9,076
Extraordinary item, net of
income taxes (5)........... - (1,569) - - - - -
-------- -------- -------- ------- ------- ------- -------
Net income (loss).......... $(7,065) $17,808 $27,159 $19,314 $24,406 $6,003 $9,076
======== ======== ======== ======= ======= ======= =======

Earnings (Loss) Per Share Before Extraordinary Item:

Basic ........................ $ (0.31) $ 0.86 $ 1.19 $ 0.84 $ 1.02 $0.26 $0.36
======== ======== ======== ======= ======= ======= =======
Diluted....................... $ (0.31) $ 0.84 $ 1.17 $ 0.83 $ 1.00 $0.26 $0.35
======== ======== ======== ======= ======= ======= =======
Earnings (Loss) Per Share:
Basic......................... $ (0.31) $ 0.79 $ 1.19 $ 0.84 $ 1.02 $0.26 $0.36
======== ======== ======== ======= ======= ======= =======
Diluted....................... $ (0.31) $ 0.77 $ 1.17 $ 0.83 $ 1.00 $0.26 $0.35
======== ======== ======== ======= ======= ======= =======

-17-

Weighted Average Number of Common Shares In Calculating:
Basic earnings (loss) per
share...................... 22,496 22,628 22,862 22,967 24,045 23,057 25,397
======== ======== ======== ======= ======= ======= =======
Diluted earnings (loss) per
share...................... 22,496 22,982 23,145 23,271 24,401 23,307 25,969
======== ======== ======== ======= ======= ======= =======
Other Financial Data:
Depreciation and amortization. $6,954 $ 23,601 $ 26,291 $ 29,487 $ 30,148 $7,566 $5,403
Capital expenditures.......... 8,178 12,924 9,352 14,050 14,443 3,867 3,208

December 31, March 31,
------------------------------------------------------------------------
1997 1998 1999 2000 2001 2002
---- ---- ---- ---- ---- ----
(in thousands)
(unaudited)

Balance Sheet Data (6):
Cash and cash equivalents..... $ 13,452 $ 5,906 $ 3,747 $ 3,470 $ 1,402 $ 2,634
Working capital............... 95,333 93,424 109,526 113,755 44,712 47,434
Total assets.................. 561,637 628,784 662,161 679,571 701,608 706,950
Long-term debt (including
current portion)........... 365,000 384,872 394,669 378,748 335,929 325,991
Total shareholders' equity ... 162,736 182,168 211,261 230,603 283,634 295,211

_____________

(1) Includes, based on the purchase method of accounting, the results of (i)
the surgical suction product line acquired from the Davol subsidiary of
C.R. Bard, Inc., from July 1997; (ii) Linvatec Corporation acquired from
Bristol-Myers Squibb Company, from December 1997; (iii) the arthroscopy
product line acquired from 3M Company, from November 1998; (iv) the
powered instrument product line acquired from 3M Company, from August
1999; and (v) the minimally invasive surgical product lines acquired from
Imagyn Medical Technologies, Inc. in November 2000 and July 2001, in each
such case from the date of acquisition.

(2) Includes for 1998, $3,000,000 of incremental expense related to the excess
of the fair value at the acquisition date of Linvatec inventory over the
cost to produce; includes for 1999, $1,600,000 of incremental expense
related to the excess of the fair value at the acquisition date over the
cost to produce inventory related to the powered instrument product line
acquired from 3M; and includes for 2001, $1,567,000 of transition expenses
related to the July 2001 acquisition from Imagyn.

(3) Included in unusual items for 1997 are a $34,000,000 non-cash acquisition
charge for the write-off of all of the in-process research and development
products (comprised of products in the development stage) acquired in the
Linvatec acquisition, a $914,000 write-off of deferred financing fees
resulting from refinancing our loan agreements in connection with the
Linvatec acquisition, and a $2,328,000 charge for the closing of our
Dayton, Ohio manufacturing facility. Included in selling and administrative
expense for 1999 is a $1,256,000 benefit related to a previously recorded
litigation accrual which was settled on favorable terms. Included in
selling and administrative expense for 2000 is a severance charge of
$1,509,000 related to the restructuring of the Company's arthroscopy sales
force.

(4) Effective January 1, 2002, the provisions of SFAS 142 relative
to the cessation of amortization for goodwill and certain intangibles.
Had we accounted for goodwill and certain intangibles in accordance with
SAFS 142 for all periods presented, income (loss) before extraordinary
item would have been $(5,502) in 1997, $24,011 in 1998, $32,227 in 1999,
$24,969 in 2000, $30,061 in 2001 and $7,416 in the three months ended
March 31,2001. Had we accounted for goodwill and certain intangibles in
accordance with SAFS 142 for all periods presented, netincome (loss)
would have been $(5,502) in 1997, $24,011 in 1998, $32,227 in 1999,
$24,969 in 2000, $30,061 in 2001 and $7,416 in the three months ended
March 31,2001.

(5) In March 1998, we recorded an extraordinary item of $1,569,000 net of
income taxes related to the write-off of deferred financing fees.

-18-

(6) Linvatec is included in the Balance Sheet Data as of December 31, 1997, its
date of acquisition, after a one-time non-cash acquisition charge of
$34,000,000.

-19-

MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our
"Selected Financial Data" and our consolidated financial statements.

Critical Accounting Policies

The accounting policies discussed below are considered by management to
be critical to understanding our financial condition and results of operations.

Accounts receivable sale

There are certain statistical ratios, primarily related to sales
dilution and losses on accounts receivable, which must be calculated and
maintained on the pool of receivables in order to continue selling to the
conduit purchaser. Management believes that additional accounts receivable
arising in the normal course of business will be of sufficient quality and
quantity to qualify for sale under the accounts receivable sales agreement. In
the event that new accounts receivable arising in the normal course of business
do not qualify for sale, then collections on sold receivables will flow to the
conduit purchaser rather than being used to fund new receivable purchases. If
this were to occur, we would need to access an alternate source of working
capital.

Goodwill and other intangible assets

Goodwill represents the excess of purchase price over fair value of
identifiable net assets of acquired businesses. Other intangible assets
primarily represent allocations of purchase price to identifiable intangible
assets of acquired businesses. Goodwill and other intangible assets have been
amortized over periods ranging from 5 to 40 years. Because of our history of
growth through acquisitions, goodwill and other intangible assets comprise a
substantial portion (62.4% at March 31, 2002) of our total assets.

In June 2001, the Financial Accounting Standards Board approved
Statement of Financial Accounting Standards No. 142 "Goodwill and Other
Intangible Assets", or SFAS 142. We adopted SFAS 142 effective January 1, 2002.
Under this standard, amortization of goodwill and certain intangible assets,
including certain intangibles recorded as a result of past business
combinations, is to be discontinued upon adoption of SFAS 142. In addition, in
accordance with the transition provisions of

-20-

SFAS 142, goodwill recorded as a result of our acquisition of certain product
lines from Imagyn Medical Technologies, Inc. in July 2001 (the "second Imagyn
acquisition") has not been amortized.

During the quarter ended March 31, 2002, we performed tests of goodwill
and indefinite-lived intangible assets as of January 1, 2002. We tested for
impairment using the two-step process prescribed in SFAS 142. The first step is
a screen for potential impairment. The second step, which has been determined
not to be necessary, measures the amount of any impairment. No impairment losses
have been recognized as a result of these tests. During the quarter ended March
31, 2002, net income increased by approximately $1.4 million or $.05 per share
as a result of the adoption of SFAS 142.

Derivative financial instruments

Effective January 1, 2001, we adopted Statement of Financial Accounting
Standards No. 133, Accounting for Derivative Instruments and Hedging Activities,
or SFAS 133. SFAS 133 requires that derivatives be recorded on the balance sheet
as assets or liabilities, measured at fair value. Gains or losses resulting from
the changes in the values of the derivatives are accounted for depending on
whether the derivative qualifies for hedge accounting. Upon adoption of SFAS
133, we recorded a net-of-tax cumulative-effect-type loss adjustment of $l.0
million in accumulated other comprehensive income to recognize at fair value an
interest rate swap which we have designated as a cash-flow hedge and which
effectively converts $50.0 million of LIBOR-based floating rate debt under our
credit agreement into fixed rate debt with a base interest rate of 7.01%. During
the quarter ended March 31, 2002, gross holding gains were $0.1 million, before
income taxes, while holding losses of $0.6 million, before income taxes, were
reclassified and included in net income. Including the cumulative effect loss
adjustment related to the adoption of SFAS 133, total gross holding losses
during 2001 related to the interest rate swap aggregated $4.4 million before
income taxes, of which $1.3 million, before income taxes, has been reclassified
and included in net income.

Revenue recognition

Revenue is recognized when title to the goods and risk of loss pass to
our customers. Amounts billed to customers related to shipping and handling
costs are included in net sales. We assess the risk of loss on accounts
receivable and adjust the allowance for doubtful accounts based on this risk
assessment. Historically, losses on accounts receivable have not been material.
Management believes the allowance for doubtful accounts of $1.5 million at March
31, 2002 is adequate to provide for any potential losses from accounts
receivable.

Results of Operations

Three months ended March 31, 2002 compared to three months ended March 31, 2001

The following table presents, as a percentage of net sales, certain
categories included in our unaudited consolidated statements of income for the
periods indicated:

Three Months Ended March 31,
2001 2002
----------- ----------
(unaudited)

Net sales...................................... 100.0% 100.0%
Cost of sales.................................. 46.9 47.8
----------- ----------
Gross margin.............................. 53.1 52.2

-21-

Selling and administrative expense............. 32.9 30.4
Research and development expense............... 3.5 3.4
----------- ----------
Income from operations.................... 16.7 18.4
Interest expense, net.......................... 7.8 5.9
----------- ----------
Income before income taxes................ 8.9 12.5
Provision for income taxes..................... 3.2 4.5
----------- ----------
Net income................................ 5.7% 8.0%
=========== ==========

Sales for the quarter ended March 31, 2002 were $113.2 million, an
increase of 6.9% compared to sales of $105.9 million in the same quarter a year
ago. Excluding the effects of the second Imagyn acquisition, sales would have
grown by approximately 1.0%. Fluctuations in foreign currency exchange rates in
the first quarter of 2002 as compared to the same period a year ago did not have
a significant effect on sales.

o Sales in our orthopedic businesses decreased 1.6% to $69.7
million from $70.8 million in the comparable quarter last year.

o Arthroscopy sales, which represented approximately 59.3% of
total first quarter of 2002 orthopedic revenues, grew 2.7%
to $41.3 million from $40.2 million in the same period a
year ago on strength in sales of disposable products and
video equipment.

o Powered surgical instrument sales, which represented
approximately 40.7% of orthopedic revenues, decreased 7.2%
to $28.4 million in the first quarter of 2002 from $30.6
million in the same quarter last year, which was a record
quarter for powered surgical instrument sales. In the last
three quarters of 2001, powered surgical instrument sales
averaged $27.9 million per quarter. We introduced our
PowerPro(R) battery powered instrument product line in
February 2002, replacing older versions of battery powered
instruments. First shipments of this new product line
occurred in March 2002.

o Patient care sales for the three months ended March 31, 2002 were
$17.3 million, a 1.7% decline from $17.6 million in the same period a
year ago, driven primarily by declines in sales of our surgical
suction product lines as a result of significant competition and
pricing pressures. Sales of ECG and other patient care products were
largely stable in the first quarter of 2002 as compared with the same
period a year ago.

o Electrosurgery sales for the three months ended March 31, 2002 were
$16.8 million, an increase of 12.0% from $15.0 million in the first
quarter of last year, driven by strong increases in disposable
electrosurgical pencil and ground pad sales.

o Sales of endoscopy products increased to $9.4 million in the three
months ended March 31, 2002 from $2.5 million in the same period a
year ago, primarily as a result of the second Imagyn acquisition.
Sales of the Imagyn product lines contributed approximately $6.5
million in sales in the quarter ended March 31, 2002. Excluding the
impact of the second Imagyn acquisition, endoscopy sales increased
approximately 16.0%. In July 2001, concurrent with the second Imagyn
acquisition, we created a separate sales force focused on selling
endoscopy products. Previously, endoscopy products were sold through
the electrosurgery sales force. We believe the continued strong sales
growth we have

-22-

experienced in the endoscopy product lines was enhanced by the focus
provided by a separate, dedicated sales force.

Cost of sales increased to $54.1 million in the first quarter of 2002
as compared to $49.7 million in the same quarter a year ago as a result of the
increased sales described above, while gross margin percentage declined slightly
to 52.2% in the first quarter of 2002 compared to 53.1% in the first quarter of
2001, primarily as a result of decreased sales of powered surgical instruments
which carry higher gross margins than certain of our other product lines.

Selling and administrative expenses decreased to $34.5 million in the
first quarter of 2002 as compared to $34.8 million in the first quarter of 2001.
As a percentage of sales, selling and administrative expenses totaled 30.4% in
the first quarter of 2002 compared to 32.9% in the first quarter of 2001. During
the quarter ended March 31, 2002, selling and administrative expenses decreased
by approximately $2.2 million as a result of the adoption of SFAS 142. Excluding
the impact of the adoption of SFAS 142, selling and administrative expenses in
the first quarter of 2002 would have been approximately $36.7 million or 32.4%
as a percentage of sales, declining slightly when compared with the same period
a year ago, as a result of the increase in sales.

Research and development expense increased to $3.8 million in the first
quarter of 2002 as compared to $3.7 million in the first quarter of 2001. This
increase represents continued research and development efforts primarily focused
on new product development in the orthopedic product lines. As a percentage of
sales, research and development expense decreased to 3.4% in the first quarter
compared to 3.5% in the same quarter a year ago as a result of higher sales
levels.

Interest expense in the first quarter of 2002 was $6.6 million compared
to $8.3 million in the first quarter of 2001. The decrease in interest expense
is a result of lower total borrowings during the first quarter as compared to
the same period a year ago, as well as lower weighted average interest rates on
the term loans and revolving credit facility under our credit agreement which
have declined to 4.20% and 3.70%, respectively, at March 31, 2002 as compared to
7.94% and 8.14%, respectively, at March 31, 2001.

2001 Compared to 2000

The following table presents, as a percentage of net sales, certain
categories included in our consolidated statements of income for the periods
indicated:

Year Ended December 31,
2000 2001
----------- -----------

Net sales........................................... 100.0% 100.0%
Cost of sales....................................... 47.5 47.7
----------- -----------
Gross margin..................................... 52.5 52.3
Selling and administrative expense.................. 32.4 32.8
Research and development expense.................... 3.8 3.5
----------- -----------
Income from operations........................... 16.3 16.0
Interest expense, net............................... 8.7 7.2
----------- -----------
Income before income taxes....................... 7.6 8.8
Provision for income taxes.......................... 2.7 3.1
----------- -----------
Net income....................................... 4.9% 5.7%
============ ===========

-23-

Sales for 2001 were $428.7 million, an increase of 8.3% compared to
sales of $395.9 million in 2000. Excluding our acquisition of certain product
lines from Imagyn in November 2000 (the "Imagyn acquisition") and July 2001, and
adjusting for constant foreign currency exchange rates, sales would have grown
by approximately 5.2 %.

o Sales in our orthopedic businesses grew 4.3% to $269.9 million in 2001
from $258.8 million from 2000.

o Arthroscopy sales, which represented approximately 57.7% of total
2001 orthopedic revenues, grew 7.2% in 2001 to $155.6 million
from $145.1 million in 2000, on strength in sales of disposable
products and video equipment.

o Powered surgical instrument sales, which represented
approximately 42.3% of total 2001 orthopedic revenues, grew 1.0%
to $114.3 million in 2001 from $113.7 million in 2000. We believe
the weakness in sales in the powered surgical instrument product
line was a result of our aging battery-powered product offering
which has been replaced by our new PowerPro(R) battery-powered
instrument product line, as we describe above. Adjusted for
constant foreign currency exchange rates, orthopedic sales growth
in 2001 would have been approximately 5.5% compared with 2000, as
the value of the Canadian dollar and certain European currencies
weakened in comparison with the dollar.

o Patient care sales for 2001 were $69.1 million, a 1.3% increase from
$68.2 million in 2000, as modest increases in sales of our ECG and
other patient care product lines more than offset declines in sales of
surgical suction product lines which occurred as a result of
significant competition and pricing pressures.

o Electrosurgery sales for 2001 were $66.9 million, an increase of 7.0%
from $62.5 million in 2000, driven by increases in electrosurgical
pencil and other disposable product sales.

o Endoscopy sales for 2001 were $22.8 million, an increase of 256% from
$6.4 million in 2000. Excluding the impact of the Imagyn acquisitions
in November 2000 and July 2001, as described in Note 2 to our
consolidated financial statements, the increase in endoscopy sales was
approximately 13.0%.

Cost of sales increased to $204.4 million in 2001 compared to $188.2
million in 2000, primarily as a result of the increased sales volumes described
above. As discussed in Notes 2 and 11 to our consolidated financial statements,
during 2001, we incurred various non-recurring charges in connection with the
July 2001 Imagyn acquisition. These costs were primarily related to the
transition in manufacturing of the Imagyn product lines from Imagyn's Richland,
Michigan facility to our manufacturing plants in Utica, New York. Such costs
totaled approximately $1.6 million and are included in cost of sales. Excluding
the impact of these nonrecurring expenses, cost of sales for 2001 was $202.8
million. Gross margin percentage for 2001, excluding the Imagyn-related charges,
was 52.7%, a slight improvement as a result of increased sales volumes, compared
with 52.5% in 2000. Including the Imagyn-related charges, gross margin
percentage for 2001 was 52.3%.

Selling and administrative expenses increased to $140.6 million in 2001
as compared to $128.3 million in 2000. As a percentage of sales, selling and
administrative expenses totaled 32.8% in 2001 compared to 32.4% in 2000.
Excluding a non-recurring severance charge of $1.5 million recorded in 2000
related to the restructuring of our orthopedic direct sales force, as described
in Note 11 to our consolidated financial statements, selling and administrative
expenses as a percentage

-24-

of sales were 32.0% in 2000. This restructuring involved replacing our
orthopedic direct sales force with non-stocking exclusive sales agent groups in
certain geographic regions of the United States. This plan resulted in greater
sales force coverage in the affected geographic regions. The increase in selling
and administrative expense in 2001 as compared to 2000 is a result of higher
commission and other costs in 2001 as compared to 2000 associated with the
change to exclusive sales agent groups as well as increased spending on sales
and marketing programs.

Research and development expense totaled $14.8 million in 2001,
consistent with $14.9 million in 2000. As a percentage of sales, research and
development expense decreased to 3.5% in 2001 compared to 3.8% in 2000, as a
result of higher sales levels. Our research and development efforts are focused
primarily on new product development in the orthopedic product lines.

Interest expense in 2001 was $30.8 million compared to $34.3 million in
2000. The decrease in interest expense is primarily a result of lower weighted
average interest rates on the term loans and revolving credit facility under our
credit agreement, as described in Note 5 to our consolidated financial
statements, which have declined, to 4.43% and 3.93%, respectively, at December
31, 2001 as compared to 8.73% and 9.06%, respectively, at December 31, 2000
resulting in decreased interest expense.

2000 Compared to 1999

The following table presents, as a percentage of net sales, certain
categories included in our consolidated statements of income for the periods
indicated:

Year Ended December 31,
---------------------------
1999 2000
------------ -------------

Net sales........................................... 100.0% 100.0%
Cost of sales....................................... 47.4 47.5
------------ -------------
Gross margin..................................... 52.6 52.5
Selling and administrative expense.................. 29.5 32.4
Research and development expense.................... 3.2 3.8
----------- -------------
Income from operations........................... 19.9 16.3
Interest expense, net............................... 8.6 8.7
----------- -------------
Income before income taxes....................... 11.3 7.6
Provision for income taxes.......................... 4.1 2.7
----------- -------------
Net income....................................... 7.2% 4.9%
=========== =============

Sales for 2000 were $395.9 million, an increase of 5.2% compared to
sales of $376.2 million in 1999. Excluding our acquisitions of a powered
instrument line from 3M Company in August 1999, certain product lines from
Imagyn in November 2000 and adjusting for constant foreign currency exchange
rates, sales would have grown by approximately 1.3%.

o Sales in our orthopedic businesses grew 12.0% to $258.8 million in
2000 from $231.0 million in 1999.

o Arthroscopy sales, which represented approximately 56.1% of total
2000 orthopedic revenues, grew 1.0% to $145.1 million in 2000
from $144.1 million in 1999, as increases in sales of video
equipment more than offset slight declines in sales of disposable
products.

-25-

o Powered surgical instrument sales, which represented
approximately 43.9% of total 2000 orthopedic revenues, grew 30.8%
to $113.7 million in 2000 from $86.9 million in 1999. Excluding
the impact of the acquisition of the powered surgical instrument
business from 3M Company in August 1999, as described in Note 2
to our consolidated financial statements, the increase in powered
surgical instrument sales in 2000 compared to 1999 was
approximately 12.1%. Adjusted for constant foreign currency
exchange rates, orthopedic sales growth in 2000 would have been
approximately 13.4% compared with 1999 as the value of the
Canadian dollar and certain European currencies weakened in
comparison with the dollar.

o Patient care sales for 2000 were $68.2 million, a 12.6% decrease from
$78.0 million in 1999, reflecting declines in sales of our ECG and
surgical suction product lines as a result of increased competition
and pricing pressure.

o Electrosurgery sales for 2000 were $62.5 million, consistent with the
$62.4 million in 1999, reflecting generally flat generator and
disposable product sales.

o Endoscopy sales for 2000 were $6.4 million, an increase of 33.3% from
$4.8 million in 1999. Excluding the impact of the November 2000 Imagyn
acquisition, as described in Note 2 to our consolidated financial
statements, the increase in endoscopy sales in 2000 was approximately
20.8%.

Cost of sales increased to $188.2 million in 2000 compared to $178.5
million in 1999. Gross margin percentage for 2000 was 52.5%. In connection with
the August 1999 acquisition of the powered surgical instrument business from 3M
Company, as described in Note 2 to our consolidated financial statements, we
increased the acquired value of inventory by $1.6 million; this inventory was
sold in 1999 and served to increase cost of sales by $1.6 million. Excluding the
impact of this non-recurring purchase accounting adjustment, cost of sales was
$176.9 million in 1999 and gross margin percentage for 1999 was 52.9%. The
slight decline in gross margin percentage in 2000 as compared to 1999 is
primarily a result of the negative impact of foreign currency exchange rate
fluctuations discussed above. Excluding the negative impact of foreign currency
exchange rate fluctuations, gross margin percentage in 2000 would have been
52.8%.

Selling and administrative costs increased to $128.3 million in 2000 as
compared to $110.8 million in 1999. As a percentage of sales, selling and
administrative expenses totaled 32.4% in 2000 compared to 29.5% in 1999. During
2000, we recorded in selling and administrative expense, a non-recurring
severance charge of $1.5 million related to the restructuring of our orthopedic
direct sales force, as described in Note 11 to our consolidated financial
statements. This restructuring involved replacing our orthopedic direct sales
force with non-stocking exclusive sales agent groups in certain geographic
regions of the United States. This plan resulted in greater sales force coverage
in the affected geographic regions. During 1999, we recorded in selling and
administrative expense, the non-recurring $1.3 million benefit of a previously
recorded litigation accrual which was settled on favorable terms. Excluding
these non-recurring items, as a percentage of sales, selling and administrative
expense increased to 32.0% in 2000 as compared to 29.8% in 1999. This increase,
as a percentage of sales, is a result of increased spending on sales and
marketing programs, including higher commission and other costs associated with
the change to exclusive sales agent groups.

Research and development expense was $14.9 million in 2000 as compared
to $12.1 million in 1999. As a percentage of sales, research and development
expense increased to 3.8% in 2000 as

-26-

compared to 3.2% in 1999. This increase represents expanded research and
development efforts primarily focused on new product development in the
orthopedic product lines.

Interest expense in 2000 was $34.3 million compared to $32.4 million in
1999. The increase in interest expense is primarily a result of higher weighted
average interest rates on the term loans and revolving credit facility under our
credit agreement, as described in Note 5 to our consolidated financial
statements, which increased to 8.73% and 9.06%, respectively, at December 31,
2000 as compared to 8.00% and 7.45%, respectively, at December 31, 1999
resulting in increased interest expense.

Liquidity and Capital Resources

Cash generated from our operations and borrowings under our revolving
credit facility have traditionally provided the working capital for our
operations, debt service under our credit facility and the funding of our
capital expenditures. In addition, we have used term borrowings, including (1)
borrowings under our credit facility, (2) Senior Subordinated Notes issued to
refinance borrowings under our credit facility, in the case of the Linvatec
acquisition in 1997, and (3) borrowings under separate loan facilities, in the
case of real property acquisitions, to finance our acquisitions. Following the
use of the proceeds of the offering to repay term loan borrowings under our
credit facility, we expect to continue to use cash flow from our operations and
borrowings under our revolving credit facility to finance our operations, our
debt service under our credit facility and the funding of our capital
expenditures.

Our term loans under our credit facility at March 31, 2002 aggregated
$115.9 million. Our term loans are repayable quarterly over remaining terms of
approximately three years. Our credit facility also includes a $100.0 million
revolving credit facility which expires December 2002, of which $43.0 million
was available at March 31, 2002. The borrowings under the credit facility carry
interest rates based on a spread over LIBOR or an alternative base interest
rate. The weighted average interest rates at March 31, 2002 under the term loans
and the revolving credit facility were 4.20% and 3.70%, respectively.

The Senior Subordinated Notes are in aggregate principal amount of
$130.0 million, have a maturity date of March 15, 2008 and bear interest at 9.0%
per annum which is payable semi-annually.

We used term loans to purchase the property in Largo, Florida utilized
by our Linvatec subsidiary. The term loans consist of a Class A note bearing
interest at 7.50% per annum with semiannual payments of principal and interest
through June 2009, a Class C note bearing interest at 8.25% per annum compounded
semiannually through June 2009, after which semiannual payments of principal and
interest will commence, continuing through June 2019 and a seller-financed note
bearing interest at 6.50% per annum with monthly payments of principal and
interest through July 2013. The principal balances outstanding on the Class A
note, Class C note and Seller-financed note aggregate $11.7 million, $6.5
million and $4.1 million, respectively, at March 31, 2002.

Our net working capital position was $47.4 million at March 31, 2002 as
compared to $44.7 million at December 31, 2001. Included in net working capital
is $57.0 million owed on our revolving credit facility which terminates on
December 31, 2002. We have begun discussions with our bank group regarding
extending the revolving credit facility or, as an alternative, renegotiating the
entire senior credit agreement. Based on our current discussions, we believe
that we will be able to successfully complete a senior credit arrangement which
will provide sufficient capital for our business. However, because of changed
economic conditions compared to market conditions in 1997 when our present
credit agreement was completed, we expect, based on discussions with our bank
group and current market conditions, that any new facility will carry interest
costs 75 to 100 basis points higher than our present credit agreement. Based on
the amounts outstanding at March 31, 2002 under the credit agreement, an

-27-

increase of 75 to 100 basis points would result in an increase in annual
interest expense of approximately $1.3 million to $1.7 million.

On November 1, 2001, we entered into a five-year accounts receivable
sales agreement pursuant to which we and certain of our subsidiaries sell on an
ongoing basis certain accounts receivable to CONMED Receivables Corporation, a
wholly-owned special-purpose subsidiary. CRC may in turn sell up to an aggregate
$50.0 million undivided percentage ownership interest in those receivables to a
commercial paper conduit. As of March 31, 2002 and December 31, 2001, the
undivided percentage ownership interest in receivables sold by CRC to a
commercial paper conduit aggregated $40.0 million, which has been accounted for
as a sale and reflected in the balance sheet as a reduction in accounts
receivable. We used the $40.0 million in proceeds from the sale of accounts
receivable in November 2001 to repay a portion of our term loans under our
credit agreement described in Note 5 to our consolidated financial statements.
The sale of accounts receivable is expected to enable us to lower our cost of
capital by approximately $0.5 million annually by effectively accessing the
commercial paper market. There are certain statistical ratios primarily related
to sales dilution and losses on accounts receivable which must be calculated
and maintained on the pool of receivables in order to continue selling to the
conduit purchaser. Management believes that additional accounts receivable
arising in the normal course of business will be of sufficient quality and
quantity to qualify for sale under the accounts receivable sales agreement. In
the event that new accounts receivable arising in the normal course of business
do not qualify for sale, then collections on sold receivables will flow to the
conduit purchaser rather than being used to fund new receivable purchases. If
this were to occur, we would need to access an alternate source of working
capital.

Net cash provided by operations, which we also refer to as "operating
cash flow", increased to $12.4 million for the first three months of 2002
compared to $11.1 million for the same period a year ago, primarily as a result
of higher net income. Operating cash flow in the first quarter of 2002 was
positively impacted by depreciation, amortization and increases in accounts
payable and deferred income taxes. Operating cash flow in the first quarter of
2002 was negatively impacted primarily by an increase in inventory and decreases
in accrued compensation and accrued interest. The increase in inventory is
primarily related to expected increases in sales. The increases in accounts
payable and deferred income taxes and decreases in accrued compensation and
interest are primarily related to the timing of the payment of these
liabilities. Net cash provided by operations was $77.1 million in 2001.
Operating cash flow increased substantially in 2001 compared with 2000 and 1999
as a result of the sale of accounts receivable as noted above, which increased
operating cash flows by $40.0 million. Excluding the effects of the receivable
sale, operating cash flow was $37.1 million in 2001. Operating cash flow in 2001
was positively impacted primarily by depreciation, amortization and deferred
income taxes. Operating cash flow in 2001 was negatively impacted primarily as a
result of increases in inventory and accounts receivable (excluding the effects
of the receivable sale) as a result of the second Imagyn acquisition and overall
higher sales levels experienced in 2001. Net cash provided by operations was
$36.0 million in 2000. Operating cash flow in 2000 declined compared with $37.4
million in 1999 primarily as a result of lower net income in 2000 as compared to
1999. Operating cash flow in 2000 was positively impacted primarily by
depreciation, amortization and deferred income taxes. Operating cash flow in
2000 was negatively impacted primarily as a result of increased inventories and
accounts receivable as a result of overall higher sales levels in 2000 than
1999. Net cash provided by operations was $37.4 million in 1999. Operating cash
flow in 1999 was positively impacted primarily by depreciation, amortization and
deferred income taxes. Operating cash flow in 1999 was negatively impacted
primarily as a result of increases in accounts receivable and inventories. The
increase in accounts receivable and inventory was primarily related to the
increase in sales compared with the prior year.

Capital expenditures in the three months ended March 31, 2002 were $3.2
million compared to $3.9 million in the same period a year ago. Capital
expenditures for 2001, 2000 and 1999 amounted to

-28-

$14.4 million, $14.1 million, and $9.4 million. These capital expenditures
represent the ongoing capital investment requirements of our business and are
expected to continue at the rate of approximately $12.0 - $14.0 million
annually.

Net cash used by investing activities in 2000 included $6.0 million
paid related to the Imagyn acquisition. Net cash used by investing activities in
1999 included $40.6 million paid related to the acquisition of the powered
surgical instrument business from 3M Company in August 1999, as described in
Note 2 to our consolidated financial statements on Form 10K.

Financing activities in the three months ended March 31, 2002 consisted
primarily of scheduled payments of $8.9 million on our term loans and $1.0
million in repayments under our revolving credit facility. Financing activities
in the three months ended March 31, 2001 consisted primarily of scheduled
payments of $9.0 million on our term loans and $3.0 million in borrowings under
our revolving credit facility. Proceeds from the issuance of common stock
related to our employee incentive stock option plans totaled $2.0 million in the
three months ended March 31, 2002 as compared to $.5 million in the three months
ended March 31, 2001. Financing activities in 2001 include $11.0 million in
borrowings under the revolving credit facility, $36.4 million in scheduled
payments on our term loans, and $40.0 million in additional payments on our term
loans with the proceeds from the accounts receivable sale discussed above.
Financing activities in 2000 include $17.0 million in borrowings under the
revolving credit facility and $32.9 million in scheduled payments on our term
loans. Financing activities during 1999 include a $40.0 million term loan used
to fund the acquisition of the powered surgical instrument business from 3M
Company in August 1999, scheduled payments of $23.1 million on our previously
existing term loans and $8.0 million in repayments on our revolving credit
facility. Proceeds from the issuance of common stock related to our employee
incentive stock option plans totaled $1.8 million in 2001, $0.4 million in 2000
and $1.6 million in 1999, respectively.

Assuming the successful renegotiation of the revolving credit facility
discussed above, management believes that cash generated from operations, our
current cash resources and funds available under our revolving credit facility
will provide sufficient liquidity to ensure continued working capital for
operations, debt service and funding of capital expenditures in the foreseeable
future.

Contractual Obligations

There were no capital lease obligations or unconditional purchase
obligations as of March 31, 2002. The following table summarizes our contractual
obligations related to operating leases and long-term debt as of March 31, 2002:

( in thousands)
2002 2003 2004 2005 2006 Thereafter
----------- --------- ---------- --------- --------- ----------

Long-term debt.............. $ 63,368 $ 43,364 $ 36,749 $ 35,181 $ 1,943 $ 145,386
Operating lease obligations. 1,300 1,255 1,036 962 933 1,950
---------------------------- ----------- --------- ---------- --------- --------- ---------
Total contractual cash $ 64,668 $ 44,619 $ 37,785 $ 36,143 $ 2,876 $ 147,336
=========== ========= ========== ========= ========= =========
obligations..............

Included in long-term debt obligations in 2002 is $57.0 million due under our
revolving credit facility.

-29-

BUSINESS

General

We have used strategic business acquisitions to broaden our product
offerings, to increase our market share in certain product lines and to realize
economies of scale. Since 1997, we have completed six strategic business
acquisitions. The completed acquisitions, together with internal growth, have
resulted in a compound annual growth rate in net sales of 32% between 1997 and
2001.

Industry

The growth in the markets for our products is primarily driven by:

Favorable Demographics. The number of surgical procedures performed is
increasing. This growth in surgical procedures reflects demographic trends, such
as the aging of the population, and technological advancements, which result in
safer and less invasive surgical procedures. Additionally, as people are living
longer, more active lives, they are engaging in contact sports and activities
such as running, skiing, rollerblading, golf and tennis which result in injuries
with greater frequency and at an earlier age than ever before. Sales of our
surgical products represented over 85% of our total 2001 sales. See "--Our
Products."

Continued Pressure to Reduce Health Care Costs. In response to rising
health care costs, managed care companies and other third-party payers have
placed pressures on health care providers to reduce costs. As a result, health
care providers have focused on the high cost areas such as surgery. To reduce
costs, health care providers use minimally invasive techniques, which generally
reduce patient trauma, recovery time and ultimately the length of
hospitalization. Many of our products are designed for use in minimally invasive
surgical procedures. See "--Our Products." Health care providers are also
increasingly purchasing single-use, disposable products, which reduce the costs
associated with sterilizing surgical instruments and products following surgery.
The single-use nature of disposable products lowers the risk of incorrectly
sterilized instruments spreading infection into the patient and increasing the
cost of post-operative care. Approximately 75% of our sales are derived from
single-use disposable products.

In the United States, the pressure on health care providers to contain
costs has altered their purchasing patterns for general surgical instruments and
disposable medical products. Many health care providers have entered into
comprehensive purchasing contracts with fewer suppliers, which offer a broader
array of products at lower prices. In addition, many health care providers have
aligned themselves with GPOs or IHNs, which aggregate the purchasing volume of
their members in order to negotiate competitive pricing with suppliers,
including manufacturers of surgical products. We believe that these trends will
favor entities that offer a broad product portfolio. See "--Business Strategy"
below.

-30-

Competitive Strengths

o Strong Brand Recognition. We are a leading provider of
arthroscopic surgery devices, electrosurgical systems, powered
surgical instruments and ECG electrodes. Our products are sold
under leading brand names, including CONMED(R), Linvatec(R),
and Hall Surgical(R). These brand names are well recognized by
physicians for quality and service. We believe that brand
recognition helps drive demand for our products by enabling us
to build upon the reputation for quality and service
associated with these brands and gain faster acceptance when
introducing new branded products.

o Breadth of Product Offering. The breadth of our product lines
in our key product areas enables us to meet a wide range of
customer requirements and preferences. In three of our five
key product areas, we are only one of two providers that
offers a full line of products. For example, we offer a
complete set of the arthroscopy products a surgeon requires
for most arthroscopic procedures, including instrument and
repair sets, implants, shaver consoles and handpieces, video
systems and related disposables. This in turn has enhanced our
ability to market our products to surgeons, hospitals, surgery
centers, GPOs, IHNs and other customers, particularly as
institutions seek to reduce costs and to minimize the number
of suppliers.

o Successful Integration of Acquisitions. Since 1997, we have
completed six acquisitions including the 1997 acquisition of
Linvatec Corporation which more than doubled our size. These
acquisitions have enabled us to broaden our product
categories, expand our sales and distribution capabilities and
increase our international presence. Our management team,
which averages more than 15 years of experience in the health
care industry, has demonstrated a historical ability to
identify complementary acquisitions and to integrate acquired
companies into our operations.
o Extensive Marketing and Distribution
Infrastructure. We market our products domestically through
our sales force consisting of approximately 210 employee
sales representatives and an additional 90 sales
professionals employed by eight non-stocking sales agent
groups, seven of which are exclusive. All of our sales
professionals are highly trained and educated in the
applications or procedures for the products they sell. They
call directly on surgeons, hospital departments, outpatient
surgery centers and physician offices. Additionally, we have
an international presence through sales subsidiaries and
branches located in key international markets. We sell direct
to hospital customers in these markets with an employee-based
international sales force of approximately 40 sales
representatives. We also maintain distributor relationships
domestically and in numerous countries worldwide. See
"--Marketing."

-31-

o Vertically Integrated Manufacturing. We manufacture most of
our products and components. Our vertically integrated
manufacturing process has allowed us to provide quality
products, to react quickly to changes in demand and to
generate manufacturing efficiencies, including purchasing raw
materials used in a variety of disposable products in bulk. We
believe that these manufacturing capabilities allow us to
contain costs, control quality and maintain security of
proprietary processes. We continually evaluate our
manufacturing processes with the objective of increasing
automation, streamlining production and enhancing efficiency
in order to achieve cost savings, while seeking to improve
quality.

o Research and Development Expertise. Our research and
development effort is focused on introducing new products,
enhancing existing products and developing new technologies.
During the last two years, we have introduced more than 24
products and product enhancements. Our reputation as an
innovator is exemplified by our "first-to-market" product
introductions, which include the Envision(TM) Autoclave Three
Chip Camera Head, Advantage(TM) drive system, the Trident(TM)
resection ablator, the SureCharge(TM) battery sterilization
system and the 2.9 millimeter arthroscopy scope. Research and
development expenditures were $14.8 million in 2001.

Business Strategy

Our business strategy is to continue to strengthen our position as a
market leader in our key product areas. The elements of our strategy include:

o Introduce New Products and Product Enhancements. We will
continue to pursue organic growth by developing new products
and enhancing existing products to respond to customer needs
and preferences. We are continually seeking to develop new
technologies to improve durability, performance and usability
of existing products. In addition to our research and
development, we receive new ideas for products and
technologies, especially in procedure-specific areas, from
surgeons, inventors and operating room personnel.

o Pursue Strategic Acquisitions. We believe that strategic
acquisitions represent a cost-effective means of broadening
our product line. We have historically targeted companies with
proven technologies and established brand names that provide
potential sales, marketing and manufacturing synergies. Since
1997, we have completed six acquisitions, expanding our
product line to include arthroscopy products, powered surgical
instruments and most recently endoscopy products.

o Realize Manufacturing and Operating Efficiencies. We will
continue to review opportunities for consolidating product
lines and streamlining production. We believe our vertically
integrated manufacturing processes can produce further
opportunities to reduce overhead and to increase operating
efficiencies and capacity utilization.

o Maintain Strong International Sales Growth. We believe there
are significant sales opportunities for our surgical products
outside the United States. We intend to maintain our
international sales growth and increase our penetration into
international markets by utilizing our relationships with
foreign surgeons, hospitals and third-party payers, as well as
foreign distributors. In 2001, our sales outside the United
States grew by 14% and represented 29% of our 2001 sales.

-32-

Our Products

The following table sets forth the percentage of net sales for each
category of our products for 1999, 2000 and 2001:

Year Ended December 31,
----------------------------------------
1999 2000 2001
----------- ------------- ------------

Arthroscopy.......................... 38% 36% 36%
Powered surgical instruments......... 23 29 27
Electrosurgery....................... 17 16 16
Patient Care......................... 21 17 16
Endoscopy............................ 1 2 5
----------- ------------- ------------
Total.......................... 100% 100% 100%
=========== ============= ============
Net sales (in thousands)............. $376,226 $395,873 $428,722
=========== ============= ============

Arthroscopy

We offer a broad line of devices and products for use in arthroscopic
surgery. Arthroscopy refers to diagnostic and therapeutic surgical procedures
performed on joints with the use of minimally-invasive arthroscopes and related
instruments. Minimally-invasive arthroscopy procedures enable surgical repairs
to be completed with less trauma to the patient, resulting in shorter recovery
times and cost savings. About 75% of all arthroscopy is performed on the knee,
although arthroscopic procedures are increasingly performed on shoulders and
smaller joints, such as the wrist and ankle.

Our arthroscopy products include powered resection instruments,
arthroscopes, reconstructive systems, tissue repair sets, fluid management
systems, imaging products, implants and related disposable products. It is our
standard practice to transfer some of these products, such as shaver consoles
and pumps, to certain customers at no charge. These capital "placements" allow
for and accommodate the use of a variety of disposable products, such as shaver
blades, burs and pump tubing. We have benefited from the introduction of new
products and new technologies in the arthroscopic area, such as bioresorbable
screws, ablators, "push-in" and "screw-in" suture anchors, resection shavers and
cartilage repair implants.

The majority of arthroscopic procedures are performed to repair
injuries that have occurred in the joint areas of the body. Many of these
injuries are the result of sports related events or other traumas. This explains
why arthroscopy is sometimes referred to as "sports medicine."

--------------------------------------------------------------------------------
Arthroscopy
--------------------------------------------------------------------------------
Product Description Brand Name
--------------------------------------------------------------------------------

Advantage(TM)
Ablators and Shaver Electrosurgical ablators and resection ESA(TM)
Ablators ablators to resect and remove soft Sterling(R)
tissue and bone; used in knee, shoulder UltrAblator(TM)
and small joint surgery. Heatwave(TM)
Trident(TM)

Knee Reconstructive Products used in cruciate reconstructive Paramax(R)
Systems surgery; includes instrumentation, Pinn-ACL(R)
screws, pins and ligament harvesting and GraFix(TM)
preparation devices.
--------------------------------------------------------------------------------

-33-

----------------------------------------------------------------------------------------------------------------
Arthroscopy
----------------------------------------------------------------------------------------------------------------
Product Description Brand Name
----------------------------------------------------------------------------------------------------------------

Soft Tissue Repair Systems Instrument systems designed to attach specific torn Spectrum(R)
or damaged soft tissue to bone or other soft tissue Inteq(R)
in the knee, shoulder and wrist; includes Shuttle Relay(TM)
instrumentation, guides, hooks and suture devices. Blitz(R)

Fluid Management Systems Disposable tubing sets, disposable and reusable Apex(R)
inflow devices, pumps and suction/waste management Quick-Flow(R)
systems for use in arthroscopic and general surgeries. Quick-Connect(R)

Imaging Surgical video systems for endoscopic procedures; Apex(R)
includes autoclavable single and three-chip camera 8180 Series
heads and consoles, endoscopes, light sources, Envision(TM)Autoclavable
monitors, VCRs and printers. Three Chip Camera Head

Implants Products including bioabsorbable and metal BioScrew(R)
interference screws and suture anchors for attaching BioStinger(R)
soft tissue to bone in the knee, shoulder and wrist BioAnchor(R)
as well as miniscal repair. BioTwist(R)
Ultrafix(R)
Revo(R)
Super Revo(R)

Other Instruments and Forceps, graspers, punches, probes, sterilization Shutt(R)
Accessories cases and other general instruments for arthroscopic Concept(R)
procedures. TractionTower(R)
----------------------------------------------------------------------------------------------------------------

Powered Surgical Instruments

Powered surgical instruments are used to perform orthopedic,
arthroscopic and other surgical procedures, such as cutting, drilling or reaming
and are driven by electric, battery or pneumatic power. Each instrument consists
of one or more handpieces and related accessories as well as disposable and
limited reuse items (e.g., burs, saw blades, drills and reamers). Powered
instruments are generally categorized as either small bone, large bone or
specialty powered instruments. Specialty powered instruments include surgical
applications such as spine, neurosurgery, otolaryngology (ENT),
oral/maxillofacial surgery, and cardiothoracic surgery.

Our line of powered instruments is sold principally under the Hall(R)
Surgical brand name, for use in large and small bone orthopedic, arthroscopic,
oral/maxillofacial, podiatric, plastic, otolaryngologic, neurological, spine and
cardiothoracic surgeries. Large bone, neurosurgical, spine and cardiothoracic
powered instruments are sold primarily to hospitals while small bone
arthroscopic, otolaryngological and oral/maxillofacial powered instruments are
sold to hospitals, outpatient facilities and physician offices. Our Linvatec
subsidiary has devoted substantial resources to developing a new technology base
for large

-34-

bone, small bone, arthroscopic, neurosurgical, spine and otolaryngological
instruments that can be easily adapted and modified for new procedures.

Our powered instruments line also includes our recently introduced
PowerPro(R) Battery System, which is a full function orthopedic power system
specifically designed to meet the requirements of most orthopedic applications.
The PowerPro(R) Battery System has a Surecharge(TM) option that allows the user
to sterilize the battery before it is charged. This ensures that the battery
will be fully charged when delivered to the operating room, unlike other battery
systems currently available on the market. The PowerPro(R) uses a process we
invented for maintaining sterility during the charging process, thus avoiding
the loss of battery charge during sterilization, which frequently results in
competing battery systems during sterilization.

----------------------------------------------------------------------------------------------------------
Powered Surgical Instruments
----------------------------------------------------------------------------------------------------------
Product Description Brand Name

----------------------------------------------------------------------------------------------------------

Hall(R) Surgical
Large Bone Powered saws, drills and related disposable MaxiDriver(TM)
accessories for use primarily in total knee and hip VersiPower(R)Plus
joint replacements and trauma surgical procedures. Series 4(R)
PowerPro(R)
Advantage(TM)
SureCharge(TM)

Small Bone Powered saws, drills and related disposable Hall(R)Surgical
accessories for small bones and joint surgical E9000(R)
procedures. MiniDriver(TM)
MicroChoice(R)
Micro 100(TM)
Advantage(TM)

Otolaryngology Neurosurgery Specialty powered saws, drill and related disposable Hall(R)Surgical
Spine accessories for use in neurosurgery, spine, and E9000(R)
otolaryngologic procedures. UltraPower(R)
Hall Osteon(R)
Hall Ototome(R)

Cardiothoracic Powered sternum saws, drills, and related disposable Hall(R)Surgical
Oral/maxillofacial accessories for use by cardiothoracic and E9000(R)
oral/maxillofacial surgeons. UltraPower(R)
Micro 100(TM)
VersiPower(R)Plus
----------------------------------------------------------------------------------------------------------

Electrosurgery

Electrosurgery is the technique of using a high-frequency electric
current which, when applied to tissue through special instruments, can be used
to cut tissue, coagulate, or cut and coagulate simultaneously. Radio frequency
("RF") is the form of high frequency electric current that is used in
electrosurgery. An electrosurgical system consists of a generator, an active
electrode in the form of a cautery pencil or other instrument which the surgeon
uses to apply the current from the generator to the target tissue and a ground
pad to safely return the current to the generator. Electrosurgery is routinely
used in most forms of surgery, including general, dermatologic, thoracic,
orthopedic, urologic, neurosurgical, gynecological, laparoscopic, arthroscopic
and other endoscopic procedures.

-35-

Our electrosurgical products include electrosurgical pencils and
blades, ground pads, generators, the argon-beam coagulation system (ABC(R)),
and related disposable products. ABC(R) technology is a special method of
electrosurgery, which allows a faster and more complete coagulation of many
tissues as compared to conventional electrosurgery. Unlike conventional
electrosurgery, the electrical current travels in a beam of ionized argon gas,
allowing the current to be dispersed onto the bleeding tissue without the
instrument touching the tissue. Clinicians have reported notable benefits of
ABC(R) over traditional electrosurgical coagulation in certain clinical
situations, including open-heart; liver, spleen and trauma surgery.

-------------------------------------------------------------------------------------------------------------
Electrosurgery
-------------------------------------------------------------------------------------------------------------
Product Description Brand Name
-------------------------------------------------------------------------------------------------------------

Pencils Disposable and reusable instruments designed to Hand-trol(R)
deliver high-frequency electric current to cut and/or Gold Line(R)
coagulate tissue. Clear Vac(R)

Ground Pads Disposable ground pads to safely return the current Macrolyte(R)
to the generator; available in adult, pediatric and Bio-gard(R)
infant sizes. SureFit(R)

Blades Surgical blades and accessory electrodes that Ultra Clean(TM)
use a proprietary coating to eliminate tissue
buildup on the blade during surgery.

Generators Monopolar and bipolar generators for surgical EXCALIBUR Plus PC(R)
procedures performed in a hospital, physician's SABRE(R)
office or clinic setting. Hyfrecator(R)2000

Argon Beam Specialized electrosurgical generators, disposable ABC(R)
Coagulation Systems hand pieces and ground pads for enhanced non-contact Beamer Plus(R)
coagulation of tissue. System 7500(R)
ABC Flex(R)
-------------------------------------------------------------------------------------------------------------

Patient Care

We manufacture a variety of patient care products for use in monitoring
cardiac rhythms, wound care management and IV therapy. These products include
ECG electrodes and cables, wound dressings and catheter stabilization dressings.
Our patient care product lines also include disposable surgical suction
instruments and connecting tubing. The majority of our sales in this category
are derived from the sale of ECG electrodes and surgical suction instruments and
tubing. Although wound management and intravenous therapy product sales are
comparatively small, the application of these products in the operating room
complements our surgery business.

-------------------------------------------------------------------------------------------------------
Patient Care Products
-------------------------------------------------------------------------------------------------------
Product Description Brand Name
-------------------------------------------------------------------------------------------------------

ECG Monitoring Line of disposable electrodes, monitoring cables, CONMED(R)
lead wire products and accessories designed to Ultratrace(R)
transmit ECG signals from the heart to an ECG Cleartrace(R)
monitor or recorder.

-36-

Wound Care Disposable transparent wound dressings comprising ClearSite(R)
proprietary hydrogel; able to absorb 2 1/2 times its Hydrogauze(R)
weight in wound exudate. SportPatch(TM)

Patient Positioners Products that properly and safely position Airsoft(TM)
patients while in surgery.

Surgical Suction Instruments Disposable surgical suction instruments and CONMED(R)
and Tubing connecting tubing, including Yankauer, Poole, Frazier
and Sigmoidoscopic instrumentation, for use by
physicians in the majority of open surgical
procedures.

Intravenous Therapy Disposable IV drip rate gravity controller and VENI-GARD(R)
disposable catheter stabilization dressing designed MasterFlow(R)
to hold and secure an IV needle or catheter for use Stat 2(R)
in IV therapy.

Defibrillator Pads and Stimulation electrodes for use in emergency cardiac PadPro(TM)
Accessories response and for conduction studies of the heart.
-------------------------------------------------------------------------------------------------------

Endoscopy

Endoscopic surgery (also called Laparoscopic surgery) is surgery
performed without a major incision, which results in less trauma for the patient
and produces important cost savings as a result of reduced hospitalization and
therapy. Endoscopic surgery is performed on organs in the abdominal cavity such
as the gallbladder, appendix and female reproductive organs. During a procedure,
devices called "trocars" are used to puncture the abdominal wall and then are
removed, leaving in place a trocar cannula. The trocar cannula provides access
into the abdomen for camera systems and surgical instruments. Some of our
endoscopic instruments are "reposable", which means that the instrument has a
disposable and a reusable component.

Our Endoscopy products include the Reflex(R) clip applier for vessel
and duct ligation, UNIVERSAL S/I(TM) (suction/irrigation) and UNIVERSAL PLUS(R)
laparoscopic instruments, and specialized, suction/irrigation electrosurgical
instrument systems for use in laparoscopic surgery and the TROGARD Finesse(R)
which incorporates a blunt-tipped version of a trocar. The TROGARD Finesse(R)
dilates access through the body wall rather than cutting with the sharp, pointed
tips of conventional trocars. This results in smaller wounds, and less bleeding.
We also market cutting trocars, suction/irrigation accessories, laparoscopic
scissors, active electrodes, insufflation needles, linear cutters and staplers,
and ABC(R) handpieces for use in laparoscopic surgery. Disposable skin staplers
are used to close large skin incisions with surgical staples eliminating the
time consuming suturing process.

-37-

---------------------------------------------------------------------------------------------------------
Endoscopy
---------------------------------------------------------------------------------------------------------
Product Description Brand Name
---------------------------------------------------------------------------------------------------------

Trocars Disposable and reposable devices used to puncture the Finesse(R)
abdominal wall to provide access to the abdominal Reflex(R)
cavity for camera systems and instruments. Detach a Port(R)

Multi-functional Instruments for cutting and coagulating tissue by Universal(TM)
Electrosurgery and delivering high-frequency current. Instruments that Universal Plus(TM)
Suction/Irrigation instruments deliver irrigating fluid to the tissue and remove FloVac(R)
blood and fluids from the internal operating field.

Clip Appliers Disposable devices for ligating blood vessels and Reflex(R)
ducts by placing a titanium clip on the vessel

Laparoscopic Instruments Scissors, graspers Detach a Tip(R)

Skin Staplers Disposable devices that place surgical staples to Reflex(R)
close a surgical incision.

Microlaparoscopy scopes and Small laparoscopes and instruments for doing surgery MicroLap(R)
instruments through very small incisions.
---------------------------------------------------------------------------------------------------------

Marketing

In the United States, most of the Company's products are marketed
directly to more than 6,000 hospitals, and to surgeons and other health care
facilities.

Approximately 24% of the Company's revenues in 2001 were to
customers affiliated with GPOs, IHNs and other large national or regional
accounts and 1% of 2001 revenues were to the Veterans Administration and
other hospitals operated by the Federal government. For hospital inventory
management purposes, certain of our customers prefer to purchase our products
through independent third-party medical product distributors. Approximately 26%
of our 2001 revenues represents sales made through such distributors.

In order to provide a high level of expertise to the medical
specialties we serve, our domestic sales force consists of the following:

o 180 sales representatives selling arthroscopy and orthopedic powered
surgical instrument products, including 90 employee sales
representatives and 90 sales professionals employed by eight sales
agent groups.

o 60 employee sales representatives selling electrosurgery products.

o 30 employee sales representatives selling endoscopy products.

o 30 employee sales representatives selling patient care products.

-38-

Each employee sales representative has a defined geographic area and is
compensated on a commission basis or through a combination of salary and
commission. The sales force is supervised and supported by area directors. Sales
agent groups are used in the eight largest metropolitan areas of the United
States to sell our orthopedic products in their geographic territories. All of
these sales agent groups, except one, sell CONMED products exclusively. None
stock product for resale to customers as we ship product directly to customers
and carry the receivable for that group. The sales agent groups are all paid a
commission for sales made to customers in their exclusive geographic areas. Home
office sales and marketing management provide the overall direction for the
sales of our products.

We also have a corporate sales department that is responsible for
interacting with GPOs and IHNs. We have contracts with many such organizations
and believe that the lack of any individual group purchasing contract will not
adversely impact our competitiveness in the marketplace. Our sales professionals
are required to work closely with distributors where applicable and to maintain
close relationships with end-users.

The sale of our products is accompanied by initial and ongoing
in-service training of the end user. Our sales professionals are trained in the
technical aspects of our products and their uses and the procedures in which
they are used. Our sales professionals, in turn, provide surgeons and medical
personnel with information relating to the technical features and benefits of
our products.

Our international sales accounted for approximately 29% of total
revenues in 2001. Products are sold in over 100 foreign countries. International
sales efforts are coordinated through local country dealers or with direct sales
efforts. We distribute our products through sales subsidiaries and branches with
offices located in Australia, Belgium, Canada, France, Germany, Korea, Spain and
the United Kingdom. In these countries, our sales are denominated in the local
currency. In the remaining countries where our products are sold through
independent distributors, sales are denominated in United States dollars.

We sell to a diversified base of customers around the world and,
therefore, believe there is no material concentration of credit risk.

Manufacturing

We manufacture most of our products and assemble them primarily from
components we produce. We believe our vertically integrated manufacturing
process allows us to provide quality products and generate manufacturing
efficiencies by purchasing raw materials for our disposable products in bulk. We
also believe that our manufacturing capabilities allow us to contain costs,
control quality and maintain security of proprietary processes. We use various
manual and automated equipment for fabrication and assembly of our products and
are continuing to further automate our facilities.

We use a variety of raw materials in our manufacturing processes. We
work to maintain multiple suppliers for each of our raw materials and
components. None of our critical raw materials are sourced from a single
supplier.

All of our products are classified as medical devices subject to
regulation by the Food and Drug Administration. As a manufacturer of medical
devices, our manufacturing processes and facilities are subject to on-site
inspection and continuing review by the FDA for compliance with its Quality
System Regulations. Manufacturing and sales of our products outside the United
States are also subject to foreign regulatory requirements that vary from
country to country. The time required to obtain approvals from foreign countries
may be longer or shorter than that required for FDA approval, and requirements
for foreign approvals may differ from FDA requirements.

-39-

The following table provides information regarding our primary
manufacturing and administrative facilities. We believe our facilities are
adequate in terms of space and suitability for our needs over the next several
years.

Location Square Feet Own or Lease Lease Expiration
------------------------------------------------------------------------------

Utica, NY (two facilities) 650,000 Own -
Largo, FL 278,000 Own -
Rome, NY 120,000 Own -
Englewood, CO 65,000 Own -
Irvine, CA 31,000 Lease August 2003
El Paso, TX 29,000 Lease April 2005
Juarez, Mexico 25,000 Lease December 2004
Santa Barbara, CA 18,000 Lease December 2003

We believe our production and inventory practices are generally
reflective of conditions in the industry. Our products are not generally made to
order or to individual customer specifications. Accordingly, we schedule
production and stock inventory on the basis of experience and our knowledge of
customer order patterns, and our judgment as to anticipated demand. Since
customer orders must generally be filled promptly for immediate shipment,
backlog of unfilled orders is not significant to an understanding of our
business.

Research and Development Activities

During the years ended December 31, 1999, 2000 and 2001, we spent
approximately $12.1 million, $14.9 million and $14.8 million for research and
development. Our research and development department has 116 employees.

Our research and development programs focus on the development of new
products, as well as the enhancement of existing products with the latest
technology and updated designs. We are continually seeking to develop new
technologies to improve durability, performance and usability of existing
products. In addition to our own research and development, we receive new
product and technology disclosures, especially in procedure-specific areas, from
surgeons, inventors and operating room personnel. For disclosures that we deem
promising from a clinical and commercial perspective, we seek to obtain rights
to these ideas by negotiating agreements, which typically compensate the
originator of the idea through royalty payments based on a percentage of net
sales of licensed products.

We have rights to numerous U.S. patents and corresponding foreign
patents, covering a wide range of our products. We own a majority of these
patents and have licensed rights to the remainder, both on an exclusive and
non-exclusive basis. In addition, certain patents are currently licensed to
third parties on a non-exclusive basis. Due to technological advancements, we do
not rely on our patents to maintain our competitive position, and we believe
that development of new products and improvement of existing ones is and will
continue to be more important than patent protection in maintaining our
competitive position.

Competition

The market for our products is highly competitive and our customers
have numerous alternatives of supply. Many of our competitors offer a range of
products in areas other than those in which we

-40-

compete, which may make such competitors more attractive to surgeons, hospitals,
group purchasing organizations and others. In addition, many of our competitors
are larger and have greater financial resources than we do and offer a range of
products broader than our products. Because our customers are not bound by
long-term supply arrangements with us, we may not be able to shift our
production to other products following a loss of customers to our competitors.

The following chart identifies our principal competitors in each of our
key business areas:

Arthroscopy: Smith & Nephew plc
Arthrex
Stryker Corporation
Arthrocare
Johnson & Johnson's Mitek division

Powered Surgical Instruments: Stryker Corporation
Medtronic, Inc.'s Midas Rex and Xomed
divisions
Anspach

Electrosurgery: Tyco International Ltd.'s Valleylab division
3M Company
Johnson & Johnson

Patient Care: Tyco International Ltd.'s Kendall division
3M Company

Endoscopy: Tyco International Ltd.'s U.S. Surgical
division
Johnson & Johnson's Ethicon division

We believe that product design, development and improvement, customer
acceptance, marketing strategy, customer service and price are critical elements
to compete in our industry. Other alternatives, such as medical procedures or
pharmaceuticals, could at some point prove to be interchangeable alternatives to
our products.

Government Regulation

Most if not all of our products are classified as medical devices
subject to regulation by the Food and Drug Administration. Our new products
generally require FDA clearance under a procedure known as 510(k) premarketing
notification. A 510(k) premarketing notification clearance indicates FDA
agreement with an applicant's determination that the product for which clearance
has been sought is substantially equivalent to another medical device that was
on the market prior to 1976 or that has received 510(k) premarketing
notification clearance. Some products have been continuously produced, marketed
and sold since May 1976 and require no 510(k) premarketing clearance. Our
products generally are either Class I or Class II products with the FDA, meaning
that our products must meet certain FDA standards and are subject to the 510(k)
premarketing notification clearance discussed above, but are not required to be
approved by the FDA. FDA clearance is subject to continual review, and later
discovery of previously unknown problems may result in restrictions on a
product's marketing or withdrawal of the product from the market.

-41-

We have quality control/regulatory compliance groups that are tasked
with monitoring compliance with design specifications and relevant government
regulations for all of our products. We and substantially all of our products
are subject to the provisions of the Federal Food, Drug and Cosmetic Act of
1938, as amended by the Medical Device Amendments of 1976, and the Safe Medical
Device Act of 1990, as amended in 1992, and similar foreign regulations.

As a manufacturer of medical devices, our manufacturing processes and
facilities are subject to periodic on-site inspections and continuing review by
the FDA to insure compliance with Quality System Regulations as specified in
Title 21, Code of Federal Regulation (CFR) part 820. Many of our products are
subject to industry-set standards. Industry standards relating to our products
are generally formulated by committees of the Association for the Advancement of
Medical Instrumentation. We believe that our products presently meet applicable
standards. We market our products in a number of foreign markets. Requirements
pertaining to our products vary widely from country to country, ranging from
simple product registrations to detailed submissions such as those required by
the FDA. We believe that our products currently meet applicable standards for
the countries in which they are marketed.

We are subject to product recall and have made product recalls in the
past. No recall has had a material effect on our financial condition, but there
can be no assurance regulatory issues may not have a material adverse effect in
the future.

Any change in existing federal, state or foreign laws or regulations,
or in the interpretation or enforcement thereof, or the promulgation or any
additional laws or regulations could have an adverse effect on our financial
condition or results of operations.

Employees

As of December 2001, we had 2,560 full-time employees, of whom 1,754
were in manufacturing, 116 in research and development, and the balance were in
sales, marketing, executive and administrative positions. None of our employees
are represented by a union, and we consider our employee relations to be
excellent. We have never experienced any strikes or work stoppages.

-42-

MANAGEMENT

Directors and Executive Officers

Our executive officers and the members of our board of directors are as
follows:

Name Age Position
---- --- --------

Eugene R. Corasanti......... 71 Chairman of the Board and Chief Executive
Officer
Joseph J. Corasanti......... 38 President and Chief Operating Officer,
Director
William W. Abraham.......... 70 Senior Vice President
Robert D. Shallish, Jr. .... 53 Chief Financial Officer
Gerald G. Woodard........... 54 President - Linvatec
Daniel S. Jonas............. 38 Vice President - Legal Affairs and General
Counsel
Luke A. Pomilio............. 37 Vice President; Controller
Thomas M. Acey.............. 55 Secretary and Treasurer
Frank R. Williams........... 53 Vice President - Sales and Marketing for
Endoscopy
John J. Stotts.............. 45 Vice President - Marketing and Sales for
Patient Care Products
Eugene T. Starr............. 56 President - CONMED Electrosurgery
Robert E. Remmell........... 71 Director
Bruce F. Daniels............ 67 Director
William D. Matthews......... 67 Director
Stuart J. Schwartz.......... 65 Director

Eugene R. Corasanti has served as our Chairman of the Board since our
incorporation in 1970. Mr. Corasanti is also our Chief Executive Officer. Prior
to that time he was an independent public accountant. Mr. Corasanti holds a
B.B.A. degree in Accounting from Niagara University.

Joseph J. Corasanti has served as our President and Chief Operating
Officer since August 1999 and as a Director since May 1994. He also served as
our General Counsel and Vice President-Legal Affairs from March 1993 to August
1998 and our Executive Vice-President/General Manager from August 1998 to August
1999. Prior to that time he was an Associate Attorney with the law firm of
Morgan, Wenzel & McNicholas, Los Angeles, California from 1990 to March 1993.
Mr. Corasanti holds a B.A. degree in Political Science from Hobart College and a
J.D. degree from Whittier College School of Law. Joseph J. Corasanti is the son
of Eugene R. Corasanti, Chairman and Chief Executive Officer of the Company.

William W. Abraham joined us in May 1977 as General Manager. He has
served as our Vice President-Manufacturing and Engineering since June 1983. In
November of 1989 he was named Executive Vice President and in March 1993, he was
named Senior Vice President. Mr. Abraham holds a B.S. degree in Industrial
Management from Utica College.

Robert D. Shallish, Jr. joined us as Chief Financial Officer and Vice
President-Finance in December 1989 and has also served as an Assistant Secretary
since March 1995. Prior to this he was employed as Controller of Genigraphics
Corporation in Syracuse, New York since 1984. He was employed by Price
Waterhouse LLP as a certified public accountant and senior manager from 1972
through 1984. Mr. Shallish graduated with a B.A. degree in Economics from
Hamilton College and holds a Master's degree in Accounting from Syracuse
University.

-43-

Gerald G. Woodard joined us as President of Linvatec Corporation, our
wholly-owned subsidiary, in May 2000. Prior to his employment with us, Mr.
Woodard served as the President of Elekta Holdings, Inc. from March 1998 to May
2000. Previous to this position Mr. Woodard was the President of the Monitoring
and Information Systems Division of Marquette Medical Systems from November 1995
to March 1998. Mr. Woodard holds a B.G.S. degree from Indiana University.

Daniel S. Jonas joined us as General Counsel in August 1998 and in
addition became our Vice President-Legal Affairs in March 1999. In September
1999, Mr. Jonas assumed responsibility for certain of our Regulatory Affairs and
Quality Assurance. Prior to his employment with us he was a partner with the law
firm of Harter, Secrest & Emery, LLP in Syracuse from January 1998 to August
1998, having joined the firm as an Associate Attorney in 1995. Prior to that he
was an Associate Attorney at Miller, Alfano & Raspanti, P.C. in Philadelphia
from 1992 to 1995 as well as an adjunct professor of law at the University of
Pennsylvania Law School from 1991 to 1995. Mr. Jonas holds an A.B. degree from
Brown University and a J.D. from the University of Pennsylvania Law School.

Luke A. Pomilio joined us as Controller in September 1995. In addition,
in September 1999, Mr. Pomilio became a Vice President with responsibility for
certain of our manufacturing and research and development activities. Prior to
his employment with us, Mr. Pomilio served for two years as Controller of Rome
Cable Corporation, a wire and cable manufacturer. He was also employed as a
certified public accountant for seven years with Price Waterhouse LLP where he
served most recently as an audit manager. Mr. Pomilio graduated with a B.S.
degree in Accounting and Law from Clarkson University.

Thomas M. Acey has been employed by us since August 1980 and has served
as our Treasurer since August 1988 and as our Secretary since January 1993. Mr.
Acey holds a B.S. degree in Public Accounting from Utica College and prior to
joining us was employed by the certified public accounting firm of Tartaglia &
Benzo in Utica, New York.

Frank R. Williams joined us in 1974 as Sales Manager and Director of
Marketing and became Vice President-Marketing and Sales in June 1983. In
September 1989, he became Vice President-Business Development, in November 1995,
he became Vice President-Technology Assessment and in January 2000, he also
became Vice President-Research and Development and Marketing for Minimally
Invasive Surgical Products, which is now known as CONMED Endoscopy. Mr. Williams
graduated with a B.A. degree from Hartwick College in 1970 as a biology major
and did his graduate study in Human Anatomy at the University of Rochester
College of Medicine.

John J. Stotts joined us as Vice President-Marketing and Sales for
Patient Care in July 1993 and became Vice President-Marketing in December 1996.
In January 2000, Mr. Stotts became Vice President - Marketing and Sales for
Patient Care Products. Prior to his employment with us, Mr. Stotts served as
Director of Marketing and Sales for Medtronic Andover Medical, Inc. Mr. Stotts
holds a B.A. degree in Business Administration from Ohio University.

Eugene T. Starr joined us as President of CONMED Electrosurgery in July
2001. Prior to his employment with us, Mr. Starr served as President of TYCO
Healthcare Group, Canada from October 1999 (when TYCO acquired U.S. Surgical
Corporation) to January 2001. Before his position with TYCO, Mr. Starr spent 17
years with U.S. Surgical, the most recent being Vice President and General
Manager of Auto Suture Co., U.S. Surgical's Canadian subsidiary. Mr. Starr holds
a B.S. degree in Business Administration from the University of Charleston.

Robert E. Remmell has served as a Director since June 1983. Mr. Remmell
also served as our Assistant Secretary and as a non-employee officer of several
of our subsidiaries from June 1983 until

-44-

March 1, 2000, when he resigned from his position as Assistant Secretary, and
from the positions he had held in our subsidiaries. Mr. Remmell has been a
partner since January 1961 of Steates Remmell Steates & Dziekan, Utica, New
York, which has served as counsel to the Company. Mr. Remmell holds a B.A.
degree from Utica College and an L.L.B. from Syracuse University School of Law.

Bruce F. Daniels has served as a Director since August 1992. From
August 1974 to June 1997, Mr. Daniels held various executive positions,
including a position as Controller with Chicago Pneumatic Tool Company and he is
currently retired. Mr. Daniels holds a B.S. degree in Business from Utica
College.

William D. Matthews has served as a Director since August 1997. From
1986 until retiring from the positions in 1999, Mr. Matthews was the Chairman of
the Board and the Chief Executive Officer of Oneida Ltd. Mr. Matthews is a
director of Oneida Financial Corporation and formerly served as a director of
Coyne Textile Services. Mr. Matthews holds a B.A. degree from Union College and
an L.L.B. degree from Cornell University School of Law.

Stuart J. Schwartz has served as a Director since May 1998. Dr.
Schwartz is a retired physician. From 1969 to December 1997 he was engaged in
private practice as an urologist. Dr. Schwartz holds a B.A. degree from Cornell
University and a M.D. degree from SUNY Upstate Medical College, Syracuse.

As of March 29, 2002, our executive officers and directors beneficially
owned 2,165,794 shares of our common stock, representing 8.48% of the
outstanding shares of common stock, and are record owners of 521,525 shares of
our common stock, representing 2.04% of the outstanding shares of our common
stock. Giving effect to the offering, and assuming no exercise of the
underwriters' over-allotment option, these ownership percentages would decline
to 7.59% and 1.83%.

DESCRIPTION OF CAPITAL STOCK

Our authorized capital stock currently consists of 100,000,000 shares
of common stock, par value $0.01 per share, and 500,000 shares of preferred
stock, par value $0.01 per share.

Common Stock

As of March 29, 2002, there were 25,549,358 shares of our common stock
issued and outstanding held of record by 1,213 shareholders. As of March 29,
2002, an additional 424,860 shares of common stock were reserved for issuance
under our stock option plans.

Subject to the preferences, limitations and relative rights of holders
of our preferred stock described below, the holders of our common stock are
entitled, among other things,

o to share ratably in dividends if, when, and as declared by our board of
directors out of funds legally available therefore,

o to one vote for each share held of record on all matters at all
meetings of shareholders, and

o in the event of our liquidation, dissolution or winding-up, to share
ratably in the distribution of assets remaining after payment of debts
and expenses.

-45-

Holders of shares of our common stock have no cumulative voting rights or
preemptive rights to subscribe for or purchase any additional shares of capital
stock issued by us. Our transfer agent and registrar is Registrar and Transfer
Company.

Under New York law, a corporation may declare and pay dividends or make
other distributions in cash or its bonds or its property on its outstanding
shares, except when the corporation is insolvent or would thereby be made
insolvent, or when the declaration, payment or distribution would be contrary to
any restriction contained in the certificate of incorporation. Our certificate
of incorporation contains no such restriction. In general, dividends may be
declared or paid and other distributions may be made out of surplus only, so
that the net assets of the corporation remaining after such declaration, payment
or distribution shall at least equal the amount of its stated capital.

Our board of directors presently intends to retain future earnings to
finance the development of our business and does not presently intend to declare
cash dividends. Should this policy change, the declaration of cash dividends
will be determined by our board of directors in the light of conditions then
existing, including our financial requirements and condition and provisions
affecting the declaration and payment of dividends contained in debt agreements.
Our credit agreement prohibits the payment of cash dividends and further
subjects us to compliance with various financial covenants.

Preferred Stock

We are currently authorized to issue up to 500,000 shares of our
preferred stock, none of which is issued and outstanding. Our preferred stock
may be issued in one or more series by our board of directors without further
action by shareholders. Our board of directors is authorized to fix as to any
such series the dividend rate or rates, redemption prices, preferences on
liquidation, dissolution and winding-up, sinking fund terms, if any, conversion
or exchange rights, if any, voting rights and any other preferences or special
rights and qualifications.

Depending upon the rights of any preferred stock, its issuance could
have an adverse effect on holders of our common stock by delaying or preventing
a change in control, making removal of our present management more difficult or
resulting in restrictions upon the payment of dividends and other distributions
to the holders of our common stock.

Purchase and Cancellation of Warrant Issued to Bristol-Myers Squibb

In 1997, in connection with the acquisition of Linvatec, we issued to
Bristol-Myers Squibb. Company a warrant exercisable in whole or in part for up
to 1,500,000 shares of our common stock at a price of $22.82 per share. On
April 30, 2002, we agreed to purchase the warrant for $2 million in cash and
upon its repurchase, we intend to cancel it.

SHARES ELIGIBLE FOR FUTURE SALE

As of March 29, 2002, we had outstanding 25,549,358 shares of common
stock. Of those outstanding shares of common stock, 521,525 are beneficially
owned by certain persons who may be deemed "affiliates" of ours for purposes of
Rule 144 under the Securities Act of 1933, as amended, are not freely tradeable
without restriction or further registration under the Securities Act. All of
these shares are eligible for sale in the open market in accordance with Rule
144 under the Securities Act.

-46-

In general, under Rule 144 as currently in effect, any person who has
beneficially owned shares for at least one year, including persons who may be
deemed an "affiliate" of ours, is entitled to sell within any three-month period
a number of shares of our common stock that does not exceed the greater of (i)
1% of the then outstanding shares of our common stock or (ii) the average weekly
trading volume in our common stock during the four calendar weeks preceding such
sale. Such sales under Rule 144 are also subject to certain manner of sale
provisions, notice requirements and to the availability of our current public
information. In addition, any person who is not deemed our "affiliate," and who
has beneficially owned his or her shares for at least two years, is entitled to
sell such shares under Rule 144 without regard to the volume limitations, manner
of sale provisions or notice requirements.

While no predictions can be made of any effect, that open market sales
of shares or the availability of shares for sale will have on the market price
prevailing from time to time, sales of substantial amounts of our common stock
in the public market, or the perception that such sales will occur, could
adversely affect market prices and trading activities in our common stock.

-47-

UNDERWRITING

Salomon Smith Barney Inc. is acting as sole bookrunning manager and
joint lead manager of the offering, UBS Warburg LLC is acting as joint lead
manager and Salomon Smith Barney Inc. and UBS Warburg LLC, together with Needham
& Company, Inc. and First Albany Corporation are acting as representatives of
the underwriters named below. Subject to the terms and conditions stated in the
underwriting agreement dated the date of this prospectus, each underwriter named
below has agreed to purchase, and we have agreed to sell to that underwriter,
the number of shares set forth opposite the underwriter's name.

Number
Underwriter of Shares
----------- ---------

Salomon Smith Barney Inc...........
UBS Warburg LLC....................
Needham & Company, Inc.............
First Albany Corporation...........
------------------
Total.............. 3,000,000
==================

The underwriting agreement provides that the obligations of the
underwriters to purchase the shares included in this offering are subject to
approval of legal matters by counsel and to other conditions. The underwriters
are obligated to purchase all the shares (other than those covered by the
over-allotment option described below) if they purchase any of the shares.

The underwriters propose to offer some of the shares directly to the
public at the public offering price set forth on the cover page of this
prospectus and some of the shares to dealers at the public offering price less a
concession not to exceed $___ per share. The underwriters may allow, and dealers
may reallow, a concession not to exceed $___ per share on sales to other
dealers. If all of the shares are not sold at the initial offering price, the
representatives may change the public offering price and the other selling
terms.

We have granted to the underwriters an option, exercisable for 30 days
from the date of this prospectus, to purchase up to 450,000 additional shares of
common stock at the public offering price less the underwriting discount. The
underwriters may exercise the option solely for the purpose of covering
over-allotments, if any, in connection with this offering. To the extent the
option is exercised, each underwriter must purchase a number of additional
shares approximately proportionate to that underwriter's initial purchase
commitment.

We and certain of our officers and directors have agreed that, for a
period of 90 days from the date of this prospectus, subject to certain
exceptions, we and they will not, without the prior written consent of Salomon
Smith Barney, dispose of or hedge any shares of our common stock or any
securities convertible into or exchangeable for our common stock. Salomon Smith
Barney in its sole discretion may release any of the securities subject to these
lock-up agreements at any time without notice.

The common stock is quoted on the Nasdaq National Market under the
symbol "CNMD."

The following table shows the underwriting discounts and commissions
that we are to pay to the underwriters in connection with this offering. These
amounts are shown assuming both no exercise and full exercise of the
underwriters' option to purchase additional shares of common stock.

-48-

Paid by CONMED
-------------------------------------------------
No Exercise Full Exercise
----------------------- ------------------------
Per share........ $ $
Total............ $ $

In connection with the offering, Salomon Smith Barney, on behalf of the
underwriters, may purchase and sell shares of common stock in the open market.
These transactions may include short sales, syndicate covering transactions and
stabilizing transactions. Short sales involve syndicate sales of common stock in
excess of the number of shares to be purchased by the underwriters in the
offering, which creates a syndicate short position. "Covered" short sales are
sales of shares made in an amount up to the number of shares represented by the
underwriters' over-allotment option. In determining the source of shares to
close out the covered syndicate short position, the underwriters will consider,
among other things, the price of shares available for purchase in the open
market as compared to the price at which they may purchase shares through the
over-allotment option. Transactions to close out the covered syndicate short
involve either purchases of the common stock in the open market after the
distribution has been completed or the exercise of the over-allotment option.
The underwriters may also make "naked" short sales of shares in excess of the
over-allotment option. The underwriters must close out any naked short position
by purchasing shares of common stock in the open market. A naked short position
is more likely to be created if the underwriters are concerned that there may be
downward pressure on the price of the shares in the open market after pricing
that could adversely affect investors who purchase in the offering. Stabilizing
transactions consist of bids for or purchases of shares in the open market while
the offering is in progress.

The underwriters also may impose a penalty bid. Penalty bids permit the
underwriters to reclaim a selling concession from a syndicate member when
Salomon Smith Barney repurchases shares originally sold by that syndicate member
in order to cover syndicate short positions or make stabilizing purchases.

Any of these activities may have the effect of preventing or retarding
a decline in the market price of the common stock. They may also cause the price
of the common stock to be higher than the price that would otherwise exist in
the open market in the absence of these transactions. The underwriters may
conduct these transactions on the Nasdaq National Market or in the
over-the-counter market, or otherwise. If the underwriters commence any of these
transactions, they may discontinue them at any time.

In addition, in connection with this offering, some of the underwriters
(and selling group members) may engage in passive market making transactions in
the common stock on the Nasdaq National Market, prior to the pricing and
completion of this offering. Passive market making consists of displaying bids
on the Nasdaq National Market no higher than the bid prices of independent
market makers and making purchases at prices no higher than those independent
bids and effected in response to order flow. Net purchases by a passive market
maker on each day are limited to a specified percentage of the passive market
maker's average daily trading volume in the common stock during a specified
period and must be discontinued when the limit is reached. Passive market making
may cause the price of the common stock to be higher than the price that
otherwise would exist in the open market in the absence of those transactions.
If the underwriters commence passive market making transactions, they may
discontinue them at any time.

We estimate that our portion of the total expenses of this offering
will be $_______.

The underwriters have performed investment banking and advisory and
other services for us from time to time for which they have received customary
fees and expenses. An affiliate of Salomon Smith Barney is a lender and
documentation agent under our credit facility. The underwriters may, from time
to time, engage in transactions with and perform services for us in the ordinary
course of their business.

-49-

A prospectus in electronic format may be made available on the websites
maintained by one or more of the underwriters. The representatives may agree to
allocate a number of shares to underwriters for sale to their online brokerage
account holders. The representatives will allocate shares to underwriters that
may make Internet distributions on the same basis as other allocations. In
addition, shares may be sold by the underwriters to securities dealers who
resell shares to online brokerage account holders.

We have agreed to indemnify the underwriters against certain
liabilities, including liabilities under the Securities Act of 1933, or to
contribute to payments the underwriters may be required to make because of any
of those liabilities.

VALIDITY OF COMMON STOCK

The validity of the common stock offered hereby will be passed on for
us by Sullivan & Cromwell, New York, New York, special counsel to the Company,
and for the Underwriters by Cleary, Gottlieb, Steen & Hamilton, New York, New
York.

EXPERTS

The consolidated financial statements of CONMED Corporation as of
December 31, 2000 and 2001 and for each of the three years in the period ended
December 31, 2001, incorporated herein by reference from our Form 10-K, have
been so included on the reliance on the reports of PricewaterhouseCoopers LLP,
independent accountants, given on the authority of said firm as experts in
accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

The Registration Statement

We have filed a registration statement with the SEC that registers the
shares offered by this prospectus.

The registration statement that we filed with the SEC, including the
attached exhibits and schedules, contains additional relevant information about
CONMED and its shares of common stock. The SEC allows us to omit some
information included in the registration statement from this prospectus. You
should read the entire registration statement in order to obtain this additional
information.

Filings with the SEC

In addition, we file reports, proxy statements and other information
with the SEC on a regular basis. You may read and copy this information at the
following locations of the SEC:

Public Reference Room
450 Fifth Street N.W.
Room 1024
Washington, D.C. 20549

You may also obtain copies of this information by mail from the Public
Reference Section of the SEC, 450 Fifth Street, N.W., Room 1024, Washington,
D.C. 20549, at prescribed rates. Further information on the operation of the
SEC's Public Reference Room in Washington, D.C. can be obtained by calling the
SEC at l-800-SEC-0330.

-50-

The SEC also maintains an Internet world wide web site that contains
reports, proxy statements and other information about issuers, like CONMED, who
file electronically with the SEC. The address of that site is
http://www.sec.gov.

Documents Incorporated by Reference

The SEC allows us to "incorporate by reference" information into this
prospectus. This means that we can disclose important information to you by
referring you to another document filed separately with the SEC. This
information incorporated by reference is a part of this prospectus, unless we
provide you with different information in this prospectus.

This prospectus incorporates by reference the documents listed below
that we have previously filed with the SEC. They contain important information
about CONMED and its financial condition.

o CONMED's Annual Report on Form 10-K for the year ended December 31,
2001 (our "Form 10-K").

o The description of our common stock contained in our Registration
Statement on Form 8-A, dated August 5, 1987, filed with the SEC under
Section 12(b) of the Exchange Act, including any amendment or reports
filed under the Exchange Act for the purpose of updating such
description.

This prospectus also incorporates by reference additional documents
that we may file with the SEC under Sections 13(a), 13(c), 14 and 15(d) of the
Exchange Act after the time of filing of the initial registration statement and
before effectiveness of the registration statement, and after the date of this
prospectus and before the termination of this offering. These documents include
annual reports, quarterly reports and other current reports, as well as proxy
statements.

You can obtain any of the documents incorporated by reference in this
document from us or from the SEC through the SEC's web site at the address
described above. Documents incorporated by reference are available from us
without charge, excluding any exhibits to those documents unless we specifically
incorporated by reference the exhibit in this prospectus. You can obtain these
documents from us by requesting them in writing or by telephone at the following
address or number:

Secretary
CONMED Corporation
525 French Road
Utica, New York 13502-5994
Telephone: (315) 624-3207

-51-

INDEX TO FINANCIAL STATEMENTS

Report of Independent Accountants ........................................ F-2
Consolidated Balance Sheets at December 2000 and 2001 .................... F-3
Consolidated Statements of Income for the Years Ended December 1999,
2000 and 2001 ......................................................... F-4
Consolidated Statements of Shareholders' Equity for the Years Ended
December 1999, 2000 and 2001 .......................................... F-5
Consolidated Statements of Cash Flows for the Years Ended December
1999, 2000 and 2001 ................................................... F-7
Notes to Consolidated Financial Statements ............................... F-9

F-1

REPORT OF INDEPENDENT ACCOUNTANTS

To the Board of Directors and
Shareholders of CONMED Corporation

In our opinion, the accompanying consolidated balance sheets and the
related consolidated statements of income, of cash flows and of shareholders'
equity present fairly, in all material respects, the financial position of
CONMED Corporation and its subsidiaries at December 31, 2001 and 2000, and the
results of their operations and their cash flows for each of the three years in
the period ended December 31, 2001, in conformity with accounting principles
generally accepted in the United States of America. These financial statements
are the responsibility of the Company's management; our responsibility is to
express an opinion on these financial statements based on our audits. We
conducted our audits of these statements in accordance with auditing standards
generally accepted in the United States of America, which require that we plan
and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and
significant estimates made by management, and evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.

PricewaterhouseCoopers LLP

Syracuse, New York
February 5, 2002

F-2

CONMED CORPORATION
CONSOLIDATED BALANCE SHEETS
DECEMBER 2000 AND 2001
(IN THOUSANDS EXCEPT SHARE AMOUNTS)

2000 2001
--------- ---------

ASSETS
Current assets:
Cash and cash equivalents ............................ $ 3,470 $ 1,402
Accounts receivable, less allowance for doubtful
accounts of $1,479 in 2000 and $1,553 in 2001 .... 78,626 51,188
Inventories .......................................... 104,612 107,390
Deferred income taxes ................................ 1,761 1,105
Prepaid expenses and other current assets ............ 3,562 3,464
--------- ---------
Total current assets ............................. 192,031 164,549
--------- ---------
Property, plant and equipment, net ........................ 62,450 91,026
Goodwill, net ............................................. 225,801 251,140
Other intangible assets, net .............................. 195,008 189,752
Other assets .............................................. 4,281 5,141
--------- ---------
Total assets ..................................... $ 679,571 $ 701,608
========= =========

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt .................... $ 36,068 $ 73,429
Accounts payable ..................................... 20,350 19,877
Accrued compensation ................................. 9,913 11,863
Income taxes payable ................................. 1,979 2,507
Accrued interest ..................................... 5,130 4,954
Other current liabilities ............................ 4,836 7,207
--------- ---------
Total current liabilities ........................ 78,276 119,837
--------- ---------

Long-term debt ............................................ 342,680 262,500
Deferred income taxes ..................................... 12,154 18,655
Other long-term liabilities ............................... 15,858 16,982
--------- ---------
Total liabilities .................................... 448,968 417,974
--------- ---------

Shareholders' equity:
Preferred stock, par value $.01 per share; authorized
500,000 shares, none outstanding ................. -- --
Common stock, par value $.01 per share; 100,000,000
authorized; 23,028,279 and 25,261,590, issued
and outstanding in 2000 and 2001, respectively ... 230 253
Paid-in capital ...................................... 127,985 160,757
Retained earnings .................................... 103,834 128,240
Accumulated other comprehensive loss ................. (1,027) (5,197)
Lss 37,500 shares of common stock in treasury, at cost (419) (419)
--------- ---------
Total shareholders' equity ....................... 230,603 283,634
--------- ---------
Total liabilities and shareholders' equity ....... $ 679,571 $ 701,608
========= =========

See notes to consolidated financial statements.

F-3

CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
YEARS ENDED DECEMBER 1999, 2000 AND 2001
(IN THOUSANDS EXCEPT PER SHARE AMOUNTS)

1999 2000 2001
----------- ----------- -----------
Net sales ............................... $376,226 $395,873 $428,722
----------- ----------- -----------
Cost of sales ........................... 178,480 188,223 204,374
Selling and administrative expense ...... 110,842 128,316 140,560
Research and development expense ........ 12,108 14,870 14,830
----------- ----------- -----------
301,430 331,409 359,764
----------- ----------- -----------

Income from operations .................. 74,796 64,464 68,958
Interest expense, net ................... 32,360 34,286 30,824
----------- ----------- -----------
Income before income taxes .............. 42,436 30,178 38,134
Provision for income taxes .............. 15,277 10,864 13,728
----------- ----------- -----------
Net income .............................. $ 27,159 $ 19,314 $ 24,406
=========== =========== ===========

PER SHARE DATA:
Net income
Basic............................... $ 1.19 $ .84 $ 1.02
Diluted............................. 1.17 .83 1.00

See notes to consolidated financial statements.

F-4

CONMED CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
YEARS ENDED DECEMBER 1999, 2000 AND 2001
(IN THOUSANDS)

ACCUMULATED
COMMON STOCK OTHER
-------------------- PAID-IN RETAINED COMPREHENSIVE TREASURY SHAREHOLDERS'
SHARES AMOUNT CAPITAL EARNINGS INCOME (LOSS) STOCK EQUITY
------ -------- -------- -------- ------------- --------- -------------

Balance at December 1998 ............. 22,775 $ 228 $124,963 $ 57,361 $ 35 $ (419) $182,168
Exercise of stock options ......... 182 2 1,610 1,612
Tax benefit arising from
exercise of stock
options ......................... 744 744
Comprehensive income:
Foreign currency
translation adjustments ......... (422)
Net income ...................... 27,159
Total comprehensive income ........... 26,737
------ -------- -------- -------- ------------- --------- -------------

Balance at December 1999 ............. 22,957 230 127,317 84,520 (387) (419) 211,261
Exercise of stock options ......... 72 449 449
Tax benefit arising from
exercise of stock
options ......................... 219 219
Comprehensive income:
Foreign currency
translation adjustments ......... (640)
Net income ...................... 19,314
Total comprehensive
income .......................... 18,674
------ -------- -------- -------- ------------- --------- -------------

Balance at December 2000 ............. 23,029 230 127,985 103,834 (1,027) (419) 230,603

(continued)

See notes to consolidated financial statements.

(continued)

F-5

CONMED CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
YEARS ENDED DECEMBER 1999, 2000 AND 2001
(IN THOUSANDS)

Exercise of stock options ............. 259 3 1,827 1,830
Tax benefit arising from
exercise of stock options .......... 604 604
Stock issued in connection
with business
acquisitions ....................... 1,974 20 30,341 30,361

Comprehensive income:
Foreign currency
translation adjustments ............ (1,142)
Cash flow hedging (net
of income tax benefit
of $1,106) ......................... (1,966)
Minimum pension
liability (net of income
tax benefit of $597) ............... (1,062)
Net income ......................... 24,406

Total comprehensive income ............ 20,236
------ -------- --------- --------- ------------- ---------- -------------

Balance at December 2001 .............. 25,262 $ 253 $160,757 $128,240 $ (5,197) $ (419) $283,634
====== ======== ========= ========= ============= ========== =============

See notes to consolidated financial statements.

F-6

CONMED CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 1999, 2000 AND 2001
(IN THOUSANDS)

1999 2000 2001
-------- -------- --------

Cash flows from operating activities:
Net income ...................................................... $ 27,159 $ 19,314 $ 24,406
-------- -------- --------
Adjustments to reconcile net income to net cash
provided by operations:
Depreciation .................................................... 9,207 9,434 9,055
Amortization .................................................... 17,084 20,053 21,093
Deferred income taxes ........................................... 8,978 7,974 8,562
Increase (decrease) in cash flows from changes
in assets and liabilities, net of effects from
acquisitions:
Proceeds from accounts receivable the sale of ................ -- -- 40,000
Accounts receivable .......................................... (9,192) (2,166) (12,508)
Inventories .................................................. (9,086) (18,035) (4,235)
Prepaid expenses and other current assets .................... (799) 1,811 46
Accounts payable ............................................. (3,060) 3,824 (516)
Income taxes payable ......................................... 1,242 2,295 (281)
Income tax benefit of stock option exercises ................. 744 219 604
Accrued compensation ......................................... (7) 255 1,950
Accrued interest ............................................. (1,481) 542 (290)
Other assets/liabilities, net ................................ (3,348) (9,570) (10,737)
-------- -------- --------
10,282 16,636 52,743
-------- -------- --------
Net cash provided by operations .............................. 37,441 35,950 77,149
-------- -------- --------

Cash flows from investing activities:
Payments related to business acquisitions ....................... (40,585) (6,042) --
Purchases of property, plant and equipment ...................... (9,352) (14,050) (14,443)
-------- -------- --------
Net cash used by investing activities ........................ (49,937) (20,092) (14,443)
-------- -------- --------

Cash flows from financing activities:
Proceeds of long-term debt ...................................... 40,900 -- --
Borrowings (repayments) under revolving credit
facility ..................................................... (8,000) 17,000 11,000
Proceeds from issuance of common stock .......................... 1,612 449 1,830
Payments related to issuance of long-term debt .................. (661) -- --
Payments on long-term debt ...................................... (23,103) (32,921) (76,423)
-------- -------- --------
Net cash provided (used) by financing
activities ................................................. 10,748 (15,472) (63,593)
-------- -------- --------
Effect of exchange rate changes on cash and cash
equivalents ..................................................... (411) (663) (1,181)
-------- -------- --------
Net decrease in cash and cash equivalents .......................... (2,159) (277) (2,068)
Cash and cash equivalents at beginning of year ..................... 5,906 3,747 3,470
-------- -------- --------
Cash and cash equivalents at end of year ........................... $ 3,747 $ 3,470 $ 1,402
======== ======== ========

See notes to consolidated financial statements.

(continued)

F-7

Supplemental disclosures of cash flow information:
Cash paid during the year for:
Interest ........................................................ $ 32,662 $ 33,788 $ 31,135
Income taxes .................................................... 4,502 4,141 2,098

Supplemental disclosures of non-cash investing and financing activities:

As more fully described in Note 2, we acquired a business in 2001 through the
exchange of 1,950,000 shares of our common stock valued at $29.9 million.

As more fully described in Note 2, we acquired certain property in 2001 through
the assumption of approximately $22.7 million of debt and accrued interest.

See notes to consolidated financial statements.

F-8

CONMED CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 -- OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION AND OPERATIONS

The consolidated financial statements include the accounts of CONMED
Corporation and its subsidiaries ("CONMED", the "Company", "we" or "us"). All
intercompany accounts and transactions have been eliminated. CONMED Corporation
is a medical technology company specializing in instruments, implants and video
equipment for arthroscopic sports medicine, and powered surgical instruments
(drills and saws), for orthopaedic, ENT, neuro-surgery and other surgical
specialties. We are also a leading developer, manufacturer and supplier of
advanced medical devices, including RF electrosurgery systems used routinely to
cut and cauterize tissue in nearly all types of surgical procedures worldwide,
endoscopy products such as trocars, clip appliers, scissors and surgical
staplers, and a full line of ECG electrodes for heart monitoring and other
patient care products. Our products are used in a variety of clinical settings,
such as operating rooms, surgery centers, physicians' offices and critical care
areas of hospitals.

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.

CASH EQUIVALENTS

We consider all highly liquid investments with an original maturity of
three months or less to be cash equivalents.

ACCOUNTS RECEIVABLE SALE

There are certain statistical ratios which must be maintained relating
to the pool of receivables in order to continue selling to the purchaser.
Management believes that additional accounts receivable arising in the normal
course of business will be of sufficient quality and quantity to qualify for
sale under the accounts receivable sales agreement. In the event that new
accounts receivable arising in the normal course of business do not qualify for

F-9

sale, then collections on sold receivables will flow to the purchaser rather
than being used to fund new receivable purchases. If this were to occur, we
would need to access an alternate source of working capital.

INVENTORIES

Inventories are stated at the lower of cost or market, cost being
determined on the first-in, first-out basis.

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are stated at cost and depreciated using
the straight-line method over the following estimated useful lives:

Building and improvements.. 40 years
Leasehold improvements..... Remaining life of lease
Machinery and equipment.... 2 to 15 years

GOODWILL AND OTHER INTANGIBLE ASSETS

In June 2001, the Financial Accounting Standards Board approved
Statement of Financial Accounting Standards No. 142 "Goodwill and Other
Intangible Assets" ("SFAS 142"). We adopted SFAS 142 effective January 1, 2002.
Under this standard, amortization of goodwill and certain intangibles, including
certain intangibles recorded as a result of past business combinations, is to be
discontinued upon adoption of SFAS 142. In addition, goodwill and certain
intangibles recorded as a result of business combinations completed during the
six-month period ending December 2001 have not been amortized. All goodwill and
intangible assets are being tested for impairment in accordance with the
provisions of SFAS 142. No impairment losses are expected to be recognized as a
result of the tests. While we are still assessing the effect of the adoption of
SFAS 142, management believes that had SFAS 142 been in effect during 2001, net
income would have increased by approximately $5.5 million or $.22 per share.

Accumulated amortization of goodwill amounted to $23,340,000 and
$29,941,000 at December 2000 and 2001, respectively. Other intangible assets are
comprised of the following (in thousands):

2000 2001
--------- ----------
Customer relationships ....................... $ 96,712 $ 96,712
Trademarks and tradenames .................... 95,715 95,715
Patents and other intangible assets .......... 31,479 35,465
--------- ----------
223,906 227,892

Less: Accumulated amortization .............. (28,898) (38,140)
--------- ----------

Other intangible assets, net ................. $ 195,008 $ 189,752
========= ==========

F-10

DERIVATIVE FINANCIAL INSTRUMENTS

We do not trade in derivative securities. We do use interest rate swaps
to manage the interest risk associated with our variable rate debt. We accounted
for our interest rate swaps on the accrual method at December 2000, whereby the
net interest receivable or payable is recognized on a periodic basis and
included as a component of interest expense.

Effective January 1, 2001, we adopted Statement of Financial Accounting
Standard No. 133, Accounting for Derivative Instruments and Hedging Activities,
("SFAS 133"). SFAS 133 requires that derivatives be recorded on the balance
sheet as assets or liabilities, measured at fair value. Gains or losses
resulting from the changes in the values of the derivatives are accounted for
depending on whether the derivative qualifies for hedge accounting. Upon
adoption of SFAS 133, we recorded a net-of-tax cumulative-effect-type loss
adjustment of $971,000 in accumulated other comprehensive income to recognize at
fair value an interest rate swap which we have designated as a cash-flow hedge
and which effectively converts $50,000,000 of LIBOR-based floating rate debt
under our credit facility into fixed rate debt with a base interest rate of
7.01%. Including the cumulative effect loss adjustment related to the adoption
of SFAS 133, total gross holding losses during 2001 related to the interest rate
swap aggregated $4,415,000 before income taxes, of which $1,343,000, before
income taxes, has been reclassified and included in net income. Management
estimates approximately $2,000,000, before income taxes, of gross holding losses
will be reclassified and included in net income in 2002.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair values of cash and cash equivalents, accounts receivable,
accounts payable, and interest rate swaps approximates their carrying amount.
The estimated fair values and carrying amounts of long-term debt are as follows
(in thousands):

2000 2001
---------------------- ----------------------
CARRYING CARRYING
AMOUNT FAIR VALUE AMOUNT FAIR VALUE
---------- ---------- ---------- ----------
Long-term debt (including
current maturities)............. $(378,748) $(352,748) $(335,929) $(338,529)

Fair values were determined from quoted market prices or discounted cash flow
analysis.

TRANSLATION OF FOREIGN CURRENCY FINANCIAL STATEMENTS

Assets and liabilities of foreign subsidiaries have been translated
into United States dollars at the applicable rates of exchange in effect at the
end of the period reported. Revenues and expenses have been translated at the
applicable weighted average rates of exchange in effect during the period
reported. Translation adjustments are reflected in accumulated other
comprehensive income (loss). Any transaction gains and losses are included in
net income.

REVENUE RECOGNITION

Revenue is recognized when title to the goods and risk of loss pass
to our customers. Amounts billed to customers related to shipping and handling
are included in net sales. Shipping and handling costs were $9,450,000,
$8,125,000 and $8,559,000 for the years ended December 1999, 2000 and 2001,
respectively, and are included in selling and administrative expense. We
sell to a diversified base of customers around the world and, therefore,
believe there is no material concentration of credit risk. We assess the risk
of loss on accounts receivable and adjust the allowance for doubtful accounts
based on this risk assessment. Historically, losses on accounts receivable
have not been material. Management believes the allowance for doubtful
accounts of $1,553,000 at December 2001 is adequate to provide for any potential
losses from accounts receivable.

F-11

EARNINGS PER SHARE

Basic earnings per share ("EPS") is computed based on the weighted
average number of common shares outstanding for the period. Diluted EPS gives
effect to all dilutive potential shares outstanding (i.e., options and warrants)
during the period. The following is a reconciliation of the weighted average
shares used in the calculation of basic and diluted EPS (in thousands):

1999 2000 2001
------ ------ -------
Shares used in the calculation
of basic EPS (weighted
average shares outstanding) ............. 22,862 22,967 24,045
Effect of dilutive potential
securities .............................. 283 304 356
------ ------ -------
Shares used in the calculation
of diluted EPS .......................... 23,145 23,271 24,401

The shares used in the calculation of diluted EPS exclude warrants and
options to purchase shares where the exercise price was greater than the average
market price of common shares for the year. Such shares aggregated 1,989,000,
3,396,000 and 2,842,000 at December 1999, 2000 and 2001, respectively.

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform with the
presentation used in 2001.

NOTE 2 -- BUSINESS ACQUISITIONS

On August 11, 1999, we purchased certain assets of the powered surgical
instrument business of 3M Company (the "Powered Instrument acquisition") for a
purchase price of $40.0 million. The purchase price was funded through
borrowings under our credit facility (Note 5). The Powered Instrument
acquisition was accounted for using the purchase method in which the results of
operations of the acquired business are included in our consolidated results
from the date of acquisition. The acquired products, with annual revenues of
approximately $20.0 million, complement our existing powered surgical instrument
business. Goodwill associated with the Powered Instrument acquisition aggregated
approximately $34.0 million and is being amortized on a straight-line basis over
a 40-year period. In connection with the Powered Instrument acquisition, we
increased the acquired value of inventory by $1.6 million. This inventory was
sold during the quarter ended September 1999 resulting in a non-recurring
adjustment to increase cost of sales during 1999 by $1.6 million. As a result of
the adoption of SFAS 142, amortization of goodwill associated with the Powered
Instrument acquisition has been discontinued effective January 1, 2002 (Note 1).

On November 20, 2000 we acquired certain assets of the disposable
minimally invasive surgical business of Imagyn Medical Technologies, Inc. (the
"Imagyn acquisition") for a purchase price of $6.0 million. The Imagyn
acquisition was accounted for using the purchase method in which the results of
operations of the acquired business are included in our consolidated results
from the date of acquisition. The acquisition was funded through borrowings
under our revolving credit facility (Note 5). The acquired products, with annual
sales of approximately $5.0 million, complement our existing minimally invasive
surgical products business. Goodwill associated with the Imagyn acquisition
aggregated approximately $4.8 million and is being amortized on a straight-line
basis over a 40-year period. The Imagyn acquisition did not have a material
effect on earnings per share in the year ended December 2000. As a result of the
adoption of SFAS 142, amortization of goodwill associated with the Imagyn
acquisition has been discontinued effective January 1, 2002 (Note 1).

On June 11, 2001, we reached a definitive agreement to acquire the
remaining assets of the minimally invasive surgical business of Imagyn Medical
Technologies, Inc. that we did not acquire in November 2000 (the "second Imagyn
acquisition"). The results of operations of the acquired business are included
in our consolidated results from July 6, 2001, the date of acquisition. The new
products, with expected annual revenues of $18.0 to

F-12

$20.0 million, complement our existing minimally invasive surgical products
business. Under the terms of the acquisition agreement, we issued Imagyn
1,950,000 shares of CONMED common stock, valuing the transaction at $29.9
million based on the average market price of our common stock over the 2-day
period before and after the terms of the acquisition were agreed to and
announced. Goodwill associated with the second Imagyn acquisition aggregated
approximately $26.7 million. In accordance with the transition provisions of
SFAS 142, this goodwill has not been amortized. As discussed in Note 11, during
the third and fourth quarters of 2001 we incurred certain nonrecurring costs
aggregating approximately $1.5 million in connection with the second Imagyn
acquisition which are included in cost of sales. The second Imagyn acquisition
did not have a material effect on earnings per share in the year ended December
2001.

On August 3, 2001, we purchased the real estate partnerships which own
the Largo, Florida property leased by our Linvatec subsidiary for an aggregate
purchase price of $22.7 million (the "Largo acquisition"). In connection with
the acquisition, we assumed the existing debt on the property and financed the
remainder with the seller (Note 5).

NOTE 3 -- INVENTORIES

The components of inventory are as follows (in thousands):

2000 2001
------------ -------------
Raw materials ................ $ 38,278 $ 38,101
Work in process .............. 12,612 11,921
Finished goods ............... 53,722 57,368
------------ -------------
$104,612 $107,390
============ =============

NOTE 4 -- PROPERTY, PLANT AND EQUIPMENT

Details of property, plant and equipment are as follows (in thousands):

2000 2001
--------- ---------
Land ............................... $ 1,511 $ 4,004
Building and improvements .......... 27,686 67,951
Machinery and equipment ............ 63,970 68,284
Construction in progress ........... 12,283 1,955
--------- ---------
105,450 142,194
Less: Accumulated depreciation (43,000) (51,168)
--------- ---------
$ 62,450 $ 91,026
========= =========

We lease various manufacturing and office facilities and equipment
under operating leases. Rental expense on these operating leases was
approximately $2,935,000, $3,376,000 and $2,756,000 for the years ended December
1999, 2000 and 2001, respectively. The aggregate future minimum lease
commitments for operating leases at December 2001 are as follows:

YEAR ENDING DECEMBER (IN THOUSANDS):
2002..................................... $ 1,624
2003..................................... 1,255
2004..................................... 1,036
2005..................................... 962
2006..................................... 933
Thereafter............................... 1,950

F-13

NOTE 5 -- LONG TERM DEBT

We have a credit agreement with several banks providing for a
$490,000,000 senior credit facility. The senior credit facility is comprised of
four sub-facilities: (i) a $210,000,000 five-year term loan with quarterly
principal repayments; (ii) a $140,000,000 seven-year term loan with quarterly
principal repayments; (iii) a $40,000,000 six-year term loan with quarterly
principal repayments; and (iv) a $100,000,000 revolving credit facility. The
revolving credit facility expires on December 30, 2002 and therefore has been
classified in the current portion of long-term debt; it is expected to be
renegotiated during 2002. During the commitment period, we are obligated to pay
a fee of .375% per annum on the unused portion of the revolving credit facility.
As of December 2001, we had $13,300,000, $77,220,000, $34,340,000 and
$58,000,000 outstanding under the five-year term loan, the seven-year term loan,
the six year term loan and the revolving credit facility, respectively.

The borrowings under the senior credit facility carry interest rates
based on a spread over LIBOR or an alternative base interest rate. The covenants
of the senior credit facility provide for increases and decreases to this
interest rate spread based on our operating results. Additionally, certain
events of default under the credit facility limit interest rate options
available to us. The weighted average interest rates at December 2001 under the
five-year term loan, the seven-year term loan, the six year term loan and the
revolving credit facility, were 4.00%, 4.43%, 4.60% and 3.93%, respectively.

The term debt and revolving credit facility are collateralized by
substantially all of our personal property and assets, except for our accounts
receivable and related rights which are pledged in connection with the accounts
receivable sales agreement discussed in Note 1. The agreement contains covenants
and restrictions which, among other things, require maintenance of certain
working capital levels and financial ratios, prohibit dividend payments and
restrict the incurrence of certain indebtedness and other activities, including
acquisitions and dispositions. We are also required to make mandatory
prepayments from net cash proceeds from any issue of equity and asset sales.
Mandatory prepayments are to be applied first to the prepayment of the term
loans and then to reduce borrowings under the revolving credit facility.

The debt assumed in connection with the Largo acquisition (Note 2),
consists of a note bearing interest at 7.50% per annum with semiannual payments
of principal and interest through June 2009 (the "Class A note"); and a note
bearing interest at 8.25% per annum compounded semiannually through June 2009,
after which semiannual payments of principal and interest will commence,
continuing through June 2019 (the "Class C note"). Additionally, there is a
seller-financed note which bears interest at 6.50% per annum with monthly
payments of principal and interest through July 2013 (the "Seller note"). The
principal balances assumed on the Class A note, Class C note and Seller note
aggregate $12,185,000, $6,191,000 and $4,228,000, respectively, at the date of
acquisition. The principal balances outstanding related to the Largo
acquisition, aggregated $11,724,000, $6,402,000 and $4,157,000, at December 2001
on the Class A note, Class C note and Seller note respectively. The Largo
acquisition related debt is collateralized by, among other things, recorded and
unrecorded mortgage liens on the Largo property.

We have $130,000,000 of 9% Senior Subordinated Notes (the "Notes")
outstanding. The Notes mature on March 15, 2008, unless previously redeemed by
us. Interest on the Notes is payable semi-annually on March 15 and September 15
of each year. The Notes are redeemable for cash at anytime on or after March 15,
2003, at our option, in whole or in part, at the redemption prices set forth
therein, plus accrued and unpaid interest to the date of redemption.

As discussed in Note 1, we use an interest rate swap, a form of
derivative financial instrument, to manage interest rate risk. We have
designated as a cash-flow hedge, an interest rate swap which effectively
converts $50,000,000 of LIBOR-based floating rate debt under our senior credit
facility into fixed rate debt with a base

F-14

interest rate of 7.01%. The interest rate swap expires in June 2003 and is
included in liabilities on the balance sheet with a fair value approximating
$3,072,000.

Excluding the revolving credit facility which expires and is expected
to be renegotiated in 2002, the scheduled maturities of long-term debt
outstanding at December 2001 are as follows:

YEAR ENDING DECEMBER (IN THOUSANDS):
2002..................................... $ 15,429
2003..................................... 43,364
2004..................................... 36,749
2005..................................... 35,181
2006..................................... 1,943
Thereafter............................... 145,263

NOTE 6 -- INCOME TAXES

The provision for income taxes consists of the following (in
thousands):

1999 2000 2001
------- ------- -------
Current tax expense:
Federal .............................. $ 5,027 $ 1,634 $ 3,565
State ................................ 350 300 400
Foreign .............................. 922 956 1,201
------- ------- -------
6,299 2,890 5,166
Deferred income tax expense ............. 8,978 7,974 8,562
------- ------- -------
Provision for income taxes ........... $15,277 $10,864 $13,728
======= ======= =======

A reconciliation between income taxes computed at the statutory federal
rate and the provision for income taxes follows (in thousands):

1999 2000 2001
-------- --------- ---------
Tax provision at statutory
rate based on income before
income taxes and extraordinary
item .................................... $ 14,853 $ 10,562 $ 13,347
Foreign sales corporation .................. (543) (725) (894)
State taxes ................................ 257 180 270
Nondeductible intangible amortization ...... 320 321 320
Other nondeductible permanent
differences ............................. 270 200 220
Other, net ................................. 120 326 465
-------- --------- ---------
$ 15,277 $ 10,864 $ 13,728
======== ========= =========

The tax effects of the significant temporary differences which comprise
the deferred tax assets and liabilities at December 2000 and 2001 are as follows
(in thousands):

2000 2001
-------- ---------
Assets:
Receivables .................................... $ 138 $ 225
Inventory ...................................... 1,115 870
Deferred compensation .......................... 761 943
Employee benefits .............................. 221 428
Deferred rent .................................. 570 --

F-15

Additional minimum pension liability ........... -- 597
Interest rate swap ............................. -- 1,106
Other .......................................... 1,011 164
Net operating losses of acquired subsidiary .... 3,834 3,410
Valuation allowance for deferred tax assets .... (3,834) (3,410)
-------- ---------
3,816 4,333
-------- ---------

Liabilities:
Goodwill and intangible assets ................. 11,559 17,757
Depreciation ................................... 2,650 4,126
-------- ---------
14,209 21,883
-------- ---------

Net liability ........................................ $(10,393) $(17,550)
======== =========

Net operating losses related to an acquisition are subject to certain
limitations and expire over the period 2008 to 2010. Management has established
a valuation allowance of $3,410,000 to reflect the uncertainty of realizing the
benefit of certain of these carryforwards.

NOTE 7 -- SHAREHOLDERS' EQUITY

The shareholders have authorized 500,000 shares of preferred stock, par
value $.01 per share, which may be issued in one or more series by the Board of
Directors without further action by the shareholders. As of December 2001, no
preferred stock had been issued.

On August 8, 2001, our Board of Directors declared a three-for-two
split of our common stock to be effected in the form of a common stock dividend.
This dividend was payable on September 7, 2001 to shareholders of record on
August 21, 2001. Accordingly, common stock, the number of shares outstanding,
earnings per share, incentive stock option activity and the number of shares
used in the calculation of earnings per share have all been restated to
retroactively reflect the split.

In connection with the 1997 acquisition of Linvatec Corporation, we
issued to Bristol-Myers Squibb Company a ten-year warrant to purchase 1.5
million shares of our common stock at a price of $22.82 per share.

We have reserved shares of common stock for issuance to employees and
directors under four stock option plans (the "Plans"). The exercise price on all
outstanding options is equal to the quoted fair market value of the stock at the
date of grant. Stock options are non-transferable other than on death and
generally become exercisable over a five year period from date of grant and
expire ten years from date of grant.

F-16

The following is a summary of incentive stock option activity under the
Plans (in thousands, except per share amounts):

WEIGHTED-AVERAGE
NUMBER OF SHARES EXERCISE PRICE
---------------- ----------------
Outstanding at December 1998............. 2,250 $ 11.93
Granted during 1999................ 602 19.75
Forfeited.......................... (14) 15.27
Exercised.......................... (182) 8.88
---------------- ----------------

Outstanding at December 1999............. 2,656 13.96
Granted during 2000................ 684 14.05
Forfeited.......................... (209) 17.20
Exercised.......................... (72) 6.23
---------------- ----------------

Outstanding at December 2000............. 3,059 13.91
Granted during 2001................ 709 15.59
Forfeited.......................... (75) 18.86
Exercised.......................... (259) 7.07
---------------- ----------------

Outstanding at December 2001............. 3,434 $ 14.69
================ ================

Exercisable:
December 1999...................... 1,418 $ 10.89
December 2000...................... 1,674 12.31
December 2001...................... 1,954 13.59

STOCK OPTIONS WEIGHTED AVERAGE WEIGHTED STOCK OPTIONS WEIGHTED
RANGE OF EXERCISE OUTSTANDING AT REMAINING LIFE AVERAGE EXERCISABLE AT AVERAGE
PRICES DECEMBER 2001 (YEARS) EXERCISE PRICE DECEMBER 2001 EXERCISE PRICE
----------------- -------------- ---------------- -------------- -------------- --------------

Less than $5.00 42,000 1.6 $ 3.57 42,000 $ 3.57
$5.00 to $7.50 392,000 1.5 7.05 392,000 7.05
$7.50 to $10.00 287,000 7.8 9.01 224,000 8.97
$10.00 to $15.00 905,000 8.0 13.83 287,000 13.25
$15.00 to $17.50 1,000,000 6.6 16.36 638,000 16.34
$17.50 to $20.00 471,000 7.6 19.05 222,000 19.31
$20.00 to $23.00 337,000 7.4 21.07 149,000 20.87

Statement of Financial Accounting Standards No. 123, "Accounting for
Stock-Based Compensation" ("SFAS 123") defines a fair value based method of
accounting for an employee stock option whereby compensation cost is measured at
the grant date based on the fair value of the award and is recognized over the
service period. A company may elect to adopt SFAS 123 or elect to continue
accounting for its stock option or similar equity awards using the method of
accounting prescribed by Accounting Principles Board Opinion ("APB") No. 25,
"Accounting for Stock Issued to Employees", where compensation cost is measured
at the date of grant based on the excess of the market value of the underlying
stock over the exercise price. We have elected to continue to account for our
stock-based compensation plans under the provisions of APB No. 25. No
compensation expense has been recognized in the accompanying financial
statements relative to our stock option plans.

F-17

Pro forma information regarding net income and earnings per share is
required by SFAS 123 and has been determined as if we had accounted for our
employee stock options under the fair value method of that statement. The
weighted average fair value of options granted in 1999, 2000 and 2001 was $8.85,
$8.55 and $7.39, respectively. The fair value of these options was estimated at
the date of grant using a Black-Scholes options pricing model with the following
weighted-average assumptions for options granted in 1999, 2000 and 2001,
respectively: Risk-free interest rates of 6.46%, 5.06% and 4.38%; volatility
factors of the expected market price of the Company's common stock of 39.23%,
68.01% and 48.04%; a weighted-average expected life of the option of five years;
and that no dividends would be paid on common stock.

For purposes of the pro forma disclosures, the estimated fair value of
the options is amortized to expense over the options' vesting period. The
Company's pro forma information follows (in thousands, except for earnings per
share information):

1999 2000 2001
------- ------- -------
Net income - as reported........ $27,159 $19,314 $24,406
Net income - pro forma.......... 24,678 16,167 21,561

EPS - as reported:
Basic...................... 1.19 .84 1.02
Diluted.................... 1.17 .83 1.00

EPS - pro forma
Basic...................... 1.08 .70 .90
Diluted.................... 1.07 .69 .88

NOTE 8 -- BUSINESS SEGMENTS, GEOGRAPHIC AREAS AND MAJOR CUSTOMERS

CONMED's business is organized, managed and internally reported as a
single segment comprised of medical instruments and systems used in surgical and
other medical procedures. We believe our product lines have similar economic,
operating and other related characteristics.

The following is net sales information for geographic areas (in
thousands):

1999 2000 2001
-------- -------- --------
United States .................. $285,048 $288,514 $306,306
All other countries ............ 91,178 107,359 122,416
-------- -------- --------
Total .......................... $376,226 $395,873 $428,722
======== ======== ========

There were no significant investments in long-lived assets located
outside the United States at December 2000 and 2001.

NOTE 9 -- PENSION PLANS

We maintain defined benefit plans covering substantially all employees.
We make annual contributions to the plans equal to the maximum deduction allowed
for federal income tax purposes.

F-18

Net pension cost for 1999, 2000 and 2001 included the following
components (in thousands):

1999 2000 2001
------- ------- --------
Service cost - benefits earned
during the period ..................... $ 2,592 $ 2,658 $ 3,622
Interest cost on projected benefit
obligation ............................ 1,349 1,608 1,785
Expected return on plan assets .......... (1,090) (1,121) (1,211)
Net amortization and deferral ........... 41 21 166
------- ------- --------
Net pension cost ........................ $ 2,892 $ 3,166 $ 4,362
======= ======= ========

The following table sets forth the plans' funded status and amounts
recognized in the consolidated balance sheets at December 2000 and 2001 (in
thousands):

2000 2001
-------- ---------
CHANGE IN BENEFIT OBLIGATION
Projected benefit obligation at beginning of year .... $ 19,737 $ 22,949
Service cost ......................................... 2,658 3,622
Interest cost ........................................ 1,608 1,785
Actuarial loss (gain) ................................ 2,834 4,597
Benefits paid ........................................ (3,888) (3,205)
-------- ---------
Projected benefit obligation at end of year .......... $ 22,949 $ 29,748
-------- ---------

CHANGE IN PLAN ASSETS
Fair value of plan assets at beginning of year ....... $ 12,759 $ 13,077
Actual return on plan assets ......................... 312 432
Employer contribution ................................ 3,894 6,659
Benefits paid ........................................ (3,888) (3,205)
-------- ---------
Fair value of plan assets at end of year ............. $ 13,077 $ 16,963
-------- ---------

CHANGE IN FUNDED STATUS
Funded status ........................................ $ 9,872 $ 12,785
Unrecognized net actuarial loss ...................... (3,837) (9,062)
Unrecognized transition liability .................... (60) (56)
Unrecognized prior service cost ...................... (151) (140)
Additional minimum pension liability ................. -- 1,659
-------- ---------
Accrued pension cost ................................. $ 5,824 $ 5,186
======== =========

For 1999, 2000 and 2001 actuarial calculation purposes, the weighted
average discount rate was 7.0%, 7.5% and 7.0%, respectively, the expected long
term rate of return was 8.0% and the rate of increase in future compensation
levels was 4.5%.

The projected benefit obligation, accumulated benefit obligation and
fair value of plan assets for the pension plan with accumulated benefit
obligations in excess of plan assets were $16,447,000, $11,672,000 and
$8,087,000 respectively, as of December 2001. CONMED common stock valued at
$315,000 and $550,000 was held by the plans at December 2000 and 2001,
respectively.

NOTE 10 -- LEGAL MATTERS

From time to time, we have been named as a defendant in certain
lawsuits alleging product liability, patent infringement, or other claims
incurred in the ordinary course of business. Certain of these claims are

F-19

covered by various insurance policies, subject to deductible amounts and maximum
policy limits. Ultimate liability with respect to these contingencies, if any,
is not considered to be material to the consolidated financial statements of the
Company.

NOTE 11 -- UNUSUAL ITEMS

During the quarter ended December 1999, we recognized a benefit related
to a previously recorded litigation accrual which was settled on favorable
terms. This nonrecurring benefit amounted to $1,256,000, before income taxes, or
$.03 per diluted share and is included in selling and administrative expense.

During the quarter ended June 2000, we announced we would replace our
arthroscopy direct sales force with non-stocking, exclusive sales agent groups
in certain geographic regions of the United States. As a result, we incurred a
severance charge of $1,509,000, before income taxes, or $.04 per diluted share,
in the second quarter of 2000. This nonrecurring charge is included in selling
and administrative expense.

As discussed in Note 2, during the third and fourth quarters of 2001,
we incurred certain charges related to the second Imagyn acquisition. These
costs were primarily related to the transition in manufacturing of the Imagyn
product lines from Imagyn's Richland, Michigan facility to our manufacturing
plants in Utica, New York. Such costs totaled $886,000 and $681,000,
respectively, before income taxes, or $.02 per diluted share in each of the
third and fourth quarters of 2001. These nonrecurring charges are included in
cost of sales.

NOTE 12 -- SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Selected quarterly financial data for 2000 and 2001 are as follows (in
thousands, except per share amounts):

THREE MONTHS ENDED
-------------------------------------------------
MARCH JUNE SEPTEMBER DECEMBER
--------- --------- ------------ ------------
2000
Net sales.................. $102,811 $97,878 $92,838 $102,346
Gross profit............... 54,150 50,551 48,702 54,247
Net income................. 7,409 3,516 2,729 5,660
Earnings per share:
Basic................. 0.32 0.15 0.12 0.25
Diluted............... 0.32 0.15 0.12 0.24

2001
Net sales.................. $105,909 $104,171 $105,318 $113,324
Gross profit............... 56,235 54,206 53,986 59,921
Net income................. 6,003 5,734 5,015 7,654
Earnings per share:
Basic................. 0.26 0.25 0.20 0.30
Diluted............... 0.26 0.25 0.20 0.30

As discussed in Note 11, during the quarter ended June 2000, we
incurred a severance charge of $1,509,000, before income taxes, or $.04 per
diluted share, related to a restructuring of our arthroscopy sales force. This
nonrecurring charge is included in selling and administrative expense.

As discussed in Notes 2 and 11, during the third and fourth quarters of
2001, we incurred certain transition charges related to the second Imagyn
acquisition. Such costs totaled $886,000 and $681,000,

F-20

respectively, before income taxes, or $.02 per diluted share in each of the
third and fourth quarters of 2001. These nonrecurring charges are included in
cost of sales.

NOTE 13 -- GUARANTOR FINANCIAL STATEMENTS

Our credit facility and subordinated notes (the "Notes") are guaranteed
(the "Subsidiary Guarantees") by each of our subsidiaries (the "Subsidiary
Guarantors") except CRC (the "Non-Guarantor Subsidiary"). The Subsidiary
Guarantees provide that each Subsidiary Guarantor will fully and unconditionally
guarantee our obligations under the credit facility and the Notes on a joint and
several basis. Each Subsidiary Guarantor and Non-Guarantor Subsidiary is
wholly-owned by CONMED Corporation. The following supplemental financial
information sets forth on a condensed consolidating basis, consolidating balance
sheet, statement of income and statement of cash flows for the Parent Company
Only, Subsidiary Guarantors and Non-Guarantor Subsidiary and for the Company as
of December 2000 and 2001 and for the years ended December 1999, 2000 and 2001.

F-21

CONSOLIDATING CONDENSED BALANCE SHEET
DECEMBER 2000
(in thousands)

PARENT
COMPANY SUBSIDIARY COMPANY
ONLY GUARANTORS ELIMINATIONS TOTAL
--------- ---------- ------------ ---------

ASSETS
Current assets:
Cash and cash equivalents ............... $ -- $ 3,470 $ -- $ 3,470
Accounts receivable, net ................ 35,218 43,408 -- 78,626
Inventories ............................. 20,174 84,438 -- 104,612
Deferred income taxes ................... 1,761 -- -- 1,761
Prepaid expenses and other current assets 598 2,964 -- 3,562
--------- ---------- ------------ ---------
Total current assets ................. 57,751 134,280 -- 192,031
--------- ---------- ------------ ---------
Property, plant and equipment, net ......... 38,275 24,175 -- 62,450
Goodwill, net .............................. 61,651 164,150 -- 225,801
Other intangible assets, net ............... 7,498 187,510 -- 195,008
Other assets ............................... 473,408 5,217 (474,344) 4,281
--------- ---------- ------------ ---------
Total assets ............................ $ 638,583 $ 515,332 $(474,344) $ 679,571
========= ========== ============ =========

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt ....... $ 36,068 $ -- $ -- $ 36,068
Accounts payable ........................ 4,398 15,952 -- 20,350
Accrued compensation .................... 2,147 7,766 -- 9,913
Income taxes payable .................... 1,338 641 -- 1,979
Accrued interest ........................ 5,130 -- -- 5,130
Other current liabilities ............... 1,890 2,946 -- 4,836
--------- ---------- ------------ ---------
Total current liabilities ............ 50,971 27,305 -- 78,276
--------- ---------- ------------ ---------

Long-term debt ............................. 342,680 -- -- 342,680
Deferred income taxes ...................... 12,154 -- -- 12,154
Other long-term liabilities ................ 2,175 349,295 (335,612) 15,858
--------- ---------- ------------ ---------
Total liabilities ....................... 407,980 376,600 (335,612) 448,968
--------- ---------- ------------ ---------

Shareholders' equity:
Preferred stock ......................... -- -- -- --
Common stock ............................ 230 1 (1) 230
Paid-in capital ......................... 127,985 -- -- 127,985
Retained earnings ....................... 103,834 139,758 (139,758) 103,834
Accumulated other comprehensive loss .... (1,027) (1,027) 1,027 (1,027)
Less common stock in treasury, at cost .. (419) -- -- (419)
--------- ---------- ------------ ---------
Total shareholders' equity ........... 230,603 138,732 (138,732) 230,603
--------- ---------- ------------ ---------
Total liabilities and shareholders'
equity ............................. $ 638,583 $ 515,332 $(474,344) $ 679,571
========= ========== ============ =========

F-22

CONMED CORPORATION
CONSOLIDATING CONDENSED BALANCE SHEET
DECEMBER 2001
(in thousands)

PARENT NON-
COMPANY SUBSIDIARY GUARANTOR COMPANY
ONLY GUARANTORS SUBSIDIARY ELIMINATIONS TOTAL
--------- ---------- ---------- ------------ ----------

ASSETS
Current assets:
Cash and cash equivalents ....... $ -- $ 1,181 $ 221 $ -- $ 1,402
Accounts receivable, net ........ -- 7,198 43,990 -- 51,188
Inventories ..................... 23,045 84,345 -- -- 107,390
Deferred income taxes ........... 1,105 -- -- -- 1,105
Prepaid expenses and other
current assets ................ 831 2,633 -- -- 3,464
--------- ---------- ---------- ------------ ----------
Total current assets ......... 24,981 95,357 44,211 -- 164,549
--------- ---------- ---------- ------------ ----------
Property, plant and equipment, net . 45,856 45,170 -- -- 91,026
Goodwill, net ...................... 86,412 164,728 -- -- 251,140
Other intangible assets, net ....... 8,177 181,575 -- -- 189,752
Other assets ....................... 477,798 2,376 -- (475,033) 5,141
--------- ---------- ---------- ------------ ----------
Total assets .................... $ 643,224 $ 489,206 $ 44,211 $(475,033) $ 701,608
========= ========== ========== ============ ==========

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-
term debt .................... $ 72,241 $ 1,188 $ -- $ -- $ 73,429
Accounts payable ................ 5,078 14,799 -- -- 19,877
Accrued compensation ............ 3,979 7,884 -- -- 11,863
Income taxes payable ............ 2,372 135 -- -- 2,507
Accrued interest ................ 4,760 37 157 -- 4,954
Other current liabilities ....... 4,634 2,573 -- -- 7,207
--------- ---------- ---------- ------------ ----------
Total current liabilities .... 93,064 26,616 157 -- 119,837
--------- ---------- ---------- ------------ ----------

Long-term debt ..................... 241,404 21,096 -- -- 262,500
Deferred income taxes .............. 18,655 -- -- -- 18,655
Other long-term liabilities ........ 6,467 285,329 41,947 (316,761) 16,982
--------- ---------- ---------- ------------ ----------
Total liabilities ............... 359,590 333,041 42,104 (316,761) 417,974
--------- ---------- ---------- ------------ ----------

Shareholders' equity:
Preferred stock ................. -- -- -- -- --
Common stock .................... 253 1 -- (1) 253
Paid-in capital ................. 160,757 -- 2,000 (2,000) 160,757
Retained earnings ............... 128,240 158,333 107 (158,440) 128,240
Accumulated other
comprehensive loss ............ (5,197) (2,169) -- 2,169 (5,197)
Less common stock in treasury,
at cost ....................... (419) -- -- -- (419)
--------- ---------- ---------- ------------ ----------
Total shareholders' equity ... 283,634 156,165 2,107 (158,272) 283,634
--------- ---------- ---------- ------------ ----------
Total liabilities and
shareholders' equity ....... $ 643,224 $ 489,206 $ 44,211 $(475,033) $ 701,608
========= ========== ========== ============ ==========

F-23

CONMED CORPORATION
CONSOLIDATING CONDENSED STATEMENT OF INCOME
YEAR ENDED DECEMBER 1999
(in thousands)

PARENT SUBSIDIARY
COMPANY ONLY GUARANTORS ELIMINATIONS COMPANY TOTAL
------------ ---------- ------------ -------------

Net sales...................................... $ 83,612 $292,614 $ -- $376,226
------------ ---------- ------------ -------------

Cost of sales.................................. 47,178 131,302 -- 178,480

Selling and administrative expense............. 26,338 84,504 -- 110,842

Research and development expense............... 1,626 10,482 -- 12,108
------------ ---------- ------------ -------------

75,142 226,288 -- 301,430
------------ ---------- ------------ -------------

Income from operations......................... 8,470 66,326 -- 74,796

Interest expense, net.......................... -- 32,360 -- 32,360
------------ ---------- ------------ -------------

Income before income taxes..................... 8,470 33,966 -- 42,436

Provision for income taxes..................... 3,049 12,228 -- 15,277
------------ ---------- ------------ -------------

Income before equity in earnings of unconsolidated
subsidiaries.............................. 5,421 21,738 -- 27,159

Equity in earnings of unconsolidated Subsidiaries 21,738 - (21,738) --
------------ ---------- ------------ -------------

Net income..................................... $ 27,159 $ 21,738 $ (21,738) $ 27,159
============ ========== ============ =============

F-24

CONMED CORPORATION
CONSOLIDATING CONDENSED STATEMENT OF INCOME
YEAR ENDED DECEMBER 2000
(in thousands)

PARENT SUBSIDIARY
COMPANY ONLY GUARANTORS ELIMINATIONS COMPANY TOTAL
------------ ------------ ------------ -------------

Net sales...................................... $ 73,632 $322,241 $ -- $395,873
------------ ------------ ------------ -------------

Cost of sales.................................. 42,461 145,762 -- 188,223

Selling and administrative expense............. 20,015 108,301 -- 128,316

Research and development expense............... 1,907 12,963 -- 14,870
------------ ------------ ------------ -------------

64,383 267,026 -- 331,409
------------ ------------ ------------ -------------

Income from operations......................... 9,249 55,215 -- 64,464

Interest expense, net.......................... -- 34,286 -- 34,286
------------ ------------ ------------ -------------

Income before income taxes..................... 9,249 20,929 -- 30,178

Provision for income taxes..................... 3,330 7,534 -- 10,864
------------ ------------ ------------ -------------

Income before equity in earnings of unconsolidated
subsidiaries.............................. 5,919 13,395 -- 19,314

Equity in earnings of unconsolidated subsidiaries 13,395 -- (13,395) --
------------ ------------ ------------ -------------

Net income..................................... $ 19,314 $ 13,395 $(13,395) $ 19,314
============ ============ ============ =============

F-25

CONMED CORPORATION
CONSOLIDATING CONDENSED STATEMENT OF INCOME
YEAR ENDED DECEMBER 2001
(in thousands)

PARENT SUBSIDIARY NON-GUARANTOR
COMPANY ONLY GUARANTORS SUBSIDIARY ELIMINATIONS COMPANY TOTAL
------------ ---------- ---------- ------------ -------------

Net sales........................ $91,609 $337,113 $ -- $ -- $428,722
------------ ---------- ---------- ------------ -------------

Cost of sales.................... 53,534 150,840 -- -- 204,374

Selling and administrative expense 27,620 113,302 (362) - 140,560

Research and development expense. 1,511 13,319 -- -- 14,830
------------ ---------- ---------- ------------ -------------

82,665 277,461 (362) -- 359,764
------------ ---------- ---------- ------------ -------------

Income from operations........... 8,944 59,652 362 - 68,958

Interest expense, net............ -- 30,629 195 -- 30,824
------------ ---------- ---------- ------------ -------------

Income before income taxes....... 8,944 29,023 167 -- 38,134

Provision for income taxes....... 3,220 10,448 60 -- 13,728
------------ ---------- ---------- ------------ -------------

Income before equity in earnings of
unconsolidated subsidiaries... 5,724 18,575 107 -- 24,406

Equity in earnings of
unconsolidated
subsidiaries.................. 18,682 -- -- (18,682) --
------------ ---------- ---------- ------------ -------------

Net income....................... $24,406 $ 18,575 $ 107 $(18,682) $ 24,406
============ ========== ========== ============ =============

F-26

CONMED CORPORATION
CONSOLIDATING CONDENSED STATMENT OF CASH FLOWS
YEAR ENDED DECEMBER 1999
(in thousands)

PARENT SUBSIDIARY
COMPANY ONLY GUARANTORS ELIMINATIONS COMPANY TOTAL
------------ ---------- ------------ -------------

Net cash flows from operating activities....... $11,784 $ 25,657 $ -- $ 37,441
------------ ---------- ------------ -------------

Cash flows from investing activities:
Distributions to subsidiaries............. (21,885) -- 21,885 --
Payments related to business acquisitions. -- (40,585) -- (40,585)
Purchases of property, plant and equipment (4,801) (4,551) -- (9,352)
Net cash provided (used) by investing ------------ ---------- ------------ -------------
activities............................. (26,686) (45,136) 21,885 (49,937)
------------ ---------- ------------ -------------

Cash flows from financing:
Proceeds of long-term debt................ 40,900 -- -- 40,900
Distributions from parent................. -- 21,885 (21,885) --
Repayments under revolving credit facility (8,000) -- -- (8,000)
Proceeds from issuance of common stock.... 1,612 -- -- 1,612
Payments related to issuance of long-term
debt (661) -- -- (661)
Payments on long-term debt................ (23,103) -- -- (23,103)
Net cash provided (used)by financing ------------ ---------- ------------ -------------
activities............................. 10,748 21,885 (21,885) 10,748
------------ ---------- ------------ -------------

Effect of exchange rate changes on cash
and cash equivalents..................... -- (411) -- (411)
------------ ---------- ------------ -------------

Net decrease in cash and cash equivalents...... (4,154) 1,995 -- (2,159)

Cash and cash equivalents at beginning
of period................................ 4,752 1,154 -- 5,906
------------ ---------- ------------ -------------

Cash and cash equivalents at end of period..... $ 598 $ 3,149 $ -- $ 3,747
============ ========== ============ =============

F-27

CONMED CORPORATION
CONSOLIDATING CONDENSED STATEMENT OF CASH FLOWS
YEAR ENDED DECEMBER 2000
(in thousands)

PARENT SUBSIDIARY
COMPANY ONLY GUARANTORS ELIMINATIONS COMPANY TOTAL
------------ ---------- ------------ -------------

Net cash flows from operating activities....... $18,238 $17,712 $ -- $ 35,950
------------ ---------- ------------ -------------

Cash flows from investing activities:
Distributions from subsidiaries........... 13,618 -- (13,618) --
Payments related to business acquisitions. (6,042) -- -- (6,042)
Purchases of property, plant and
equipment.............................. (10,940) (3,110) -- (14,050)
Net cash provided (used) by investing ------------ ---------- ------------ -------------
activities............................. (3,364) (3,110) (13,618) (20,092)
------------ ---------- ------------ -------------

Cash flows from financing:
Distributions to parent................... -- (13,618) 13,618 --
Borrowings under revolving credit
facility............................... 17,000 -- -- 17,000
Proceeds from issuance of common stock.... 449 -- -- 449
Payments on long-term debt................ (32,921) -- -- (32,921)
Net cash provided (used) by financing ------------ ---------- ------------ -------------
activities............................. (15,472) (13,618) 13,618 (15,472)
------------ ---------- ------------ -------------

Effect of exchange rate changes on cash
and cash equivalents...................... -- (663) -- (663)
------------ ---------- ------------ -------------

Net increase (decrease) in cash and cash
equivalents............................... (598) 321 -- (277)

Cash and cash equivalents at beginning
of period................................. 598 3,149 -- 3,747
------------ ---------- ------------ -------------

Cash and cash equivalents at end of period..... $ -- $ 3,470 $ -- $ 3,470
============ ========== ============ =============

F-28

CONMED CORPORATION
CONSOLIDATING STATEMENT OF CASH FLOWS
YEAR ENDED DECEMBER 2001
(in thousands)

PARENT SUBSIDIARY NON-GUARANTOR COMPANY
COMPANY ONLY GUARANTORS SUBSIDIARY ELIMINATIONS TOTAL
------------ ---------- ---------- ------------ ----------

Net cash flows from operating activities $44,301 $ 74,574 $40,264 $(81,990) $77,149
------------ ---------- ---------- ------------ ----------

Cash flows from investing activities:
Distributions from subsidiaries... 71,629 -- -- (71,629) --
Note payable from subsidiary...... (41,947) -- -- 41,947 --
Net purchases of accounts
receivable..................... -- -- (81,990) 81,990
Purchases of property, plant
and equipment.................. (10,390) (4,053) -- -- (14,443)
Net cash provided (used) by ------------ ---------- ---------- ------------ ----------
investing activities......... 19,292 (4,053) (81,990) 52,308 (14,443)
------------ ---------- ---------- ------------ ----------

Cash flows from financing:
Distributions to parent........... -- (71,629) -- 71,629 --
Note payable to parent company.... -- -- 41,947 (41,947) --
Borrowings under revolving
credit facility................ 11,000 -- -- -- 11,000
Proceeds from issuance of
common stock................... 1,830 -- -- -- 1,830
Payments on long-term debt........ (76,423) -- -- -- (76,423)
Net cash provided (used) by ------------ ---------- ---------- ------------ ----------
financing activities........... (63,593) (71,629) 41,947 29,682 $(63,593)
------------ ---------- ---------- ------------ ----------

Effect of exchange rate changes
on cash and cash equivalents...... -- (1,181) -- -- $ (1,181)
------------ ---------- ---------- ------------ ----------

Net increase (decrease) in cash and
cash equivalents.................. -- (2,289) 221 -- (2,068)

Cash and cash equivalents at
beginning of period............... -- 3,470 -- -- 3,470
------------ ---------- ---------- ------------ ----------

Cash and cash equivalents at end of
period............................ $ -- $ 1,181 $ 221 $ -- $ 1,402
============ ========== ========== ============ ==========

F-29

================================================================================

3,000,000 Shares

CONMED Corporation

Common Stock

LOGO

------------------

PROSPECTUS

__________ ___, 2002

------------------

Salomon Smith Barney

UBS Warburg

Needham & Company, Inc.

First Albany Corporation

================================================================================

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14. Other Expenses of Issuance and Distribution*

The following are the estimated expenses of the issuance and
distribution of the securities being registered, all of which will be paid by
the Registrant.

SEC registration fee............................... $8,026
NASD filing fee.................................... 9,224
Blue sky fees and expenses.........................
Printing and engraving expenses....................
Legal fees and expenses............................
Accounting fees and expenses.......................
Transfer agent fees and expenses...................
Listing fee........................................
Miscellaneous......................................
------------

Total...................................... $
============

* All amounts are estimated except for the SEC registration fee and NASD
filing fee.

Item 15. Indemnification of Officers and Directors

Section 722 of the New York Business Corporation Law (the "New York
Law") provides that a corporation may indemnify an officer or director, in the
case of third party actions, against judgments, fines, amounts paid in
settlement and reasonable expenses and, in the case of derivative actions,
against amounts paid in settlement and reasonable expenses, if the director or
officer "acted, in good faith, for a purpose which he reasonably believed to be
in . . . the best interests of the corporation" and, in the case of criminal
actions, "had no reasonable cause to believe that his conduct was unlawful."
Statutory indemnification may not be provided in derivative actions in respect
of a threatened action, or a pending action which is settled or otherwise
disposed of, or any claim, issue or matter as to which such person shall have
been adjudged to be liable to the corporation, unless and only to the extent
that the court in which the action was brought, or, if no action was brought,
any court of competent jurisdiction, determines upon application that, in view
of all of the circumstances of the case, the person is fairly and reasonably
entitled to indemnity for such portion of the settlement and expenses as the
court deems proper.

As contemplated by New York Law Section 721, CONMED's Bylaws, as
amended on December 26, 1990, provide a broader basis for indemnification in
accordance with and as permitted by New York Law Article 7.

Section 6.6 of CONMED's Bylaws provides as follows:

Section 6.6 Indemnification. The Corporation shall indemnify
each person made or threatened to be made a party to any action or
proceeding, whether civil or criminal, by reason of the fact that such
person or such person's testator or intestate is or was a director or
officer of the Corporation, or serves or served at the request of the
Corporation, any other corporation,

II-1

partnership, joint venture, trust, employee benefit plan or other
enterprise in any capacity, against judgments, fines, penalties,
amounts paid in settlement and reasonable expenses, including
attorneys' fees, incurred in connection with such action or proceeding,
or any appeal therein, provided that no such indemnification shall be
made if a judgment or other final adjudication adverse to such person
establishes that his or her acts were committed in bad faith or were
the result of active and deliberate dishonesty and were material to the
cause of action so adjudicated, or that he or she personally gained in
fact a financial profit or other advantage to which he or she was not
legally entitled, and provided further that no such indemnification
shall be required with respect to any settlement or other
nonadjudicated disposition of any threatened or pending action or
proceeding unless the Corporation has given its prior consent to such
settlement or other disposition.

The Corporation may advance or promptly reimburse upon request
any person entitled to indemnification hereunder for all expenses,
including attorneys' fees, reasonably incurred in defending any action
or proceeding in advance of the final disposition thereof upon receipt
of an undertaking by or on behalf of such person to repay such amount
if such person is ultimately found not to be entitled to
indemnification or, where indemnification is granted, to the extent the
expenses so advanced or reimbursed exceed the amount to which such
person is entitled, provided, however, that such person shall cooperate
in good faith with any request by the Corporation that common counsel
be utilized by the parties to an action or proceeding who are similarly
situated unless to do so would be inappropriate due to actual or
potential differing interests between or among such parties.

Anything in these bylaws to the contrary notwithstanding, no
elimination of this bylaw, and no amendment of this bylaw adversely
affecting the right of any person to indemnification or advancement of
expenses hereunder, shall be effective until the 60th day following
notice to such person of such action, and no elimination of or
amendment to this bylaw shall deprive any person of his or her rights
hereunder arising out of alleged or actual occurrences, acts or
failures to act prior to such 60th day.

The Corporation shall not, except by elimination or amendment
of this bylaw in a manner consistent with the preceding paragraph, take
any corporate action or enter into any agreement which prohibits, or
otherwise limits the rights of any person to, indemnification in
accordance with the provisions of this bylaw. The indemnification of
any person provided by this bylaw shall continue after such person has
ceased to be a director, officer or employee of the Corporation and
shall inure to the benefit of such person's heirs, executors,
administrators and legal representatives.

The Corporation is authorized to enter into agreements with
any of its directors, officers or employees extending rights to
indemnification and advancement of expenses to such person to the
fullest extent permitted by applicable law as it currently exists, but
the failure to enter into any such agreement shall not affect or limit
the rights of such person pursuant to this bylaw, it being expressly
recognized hereby that all directors, officers and employees of the
Corporation, by serving as such after the adoption hereof, are acting
in reliance hereon and that the Corporation is estopped to contend
otherwise.

In case any provision in this bylaw shall be determined at any
time to be unenforceable in any respect, the other provisions shall not
in any way be affected or impaired thereby, and the affected provision
shall be given the fullest possible enforcement in the circumstances,
it being the intention of the Corporation to afford indemnification and

II-2

advancement of expenses to its directors, officers and employees,
acting in such capacities or in the other capacities mentioned herein,
to the fullest extent permitted by law.

For purposes of this bylaw, the Corporation shall be deemed to
have requested a person to serve an employee benefit plan where the
performance by such person of his or her duties to the Corporation also
imposes duties on, or otherwise involves services by, such person to
the plan or participants or beneficiaries of the plan, and excise taxes
assessed on a person with respect to an employee benefit plan pursuant
to applicable law shall be considered indemnifiable expenses. For
purposes of this bylaw, the term "Corporation" shall include any legal
successor to the Corporation, including any corporation which acquires
all or substantially all of the assets of the Corporation in one or
more transactions.

Item 16. Exhibits and Financial Statement Schedules

Exhibit No. Description
----------- -----------
1 Form of Underwriting Agreement between the Company and the
Underwriters.*
5.1 Opinion of Sullivan & Cromwell, as to validity of the common
stock.*
23.1 Consent of PricewaterhouseCoopers LLP.
23.2 Consent of Sullivan & Cromwell (included in Exhibit 5.1).
24.1 Powers of Attorney (included in the signature pages of this
Registration Statement).
----------------

* To be filed by Amendment.

Item 17. Undertakings

The undersigned registrant hereby undertakes:

(1) That, for purposes of determining any liability under the
Securities Act, each filing of the registrant's annual report pursuant
to Section 13(a) or Section 15(d) of the Securities Exchange Act (and,
where applicable, each filing of an employee benefit plan's annual
report pursuant to Section 15(d) of the Securities Exchange Act) that
is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.

(2) That, for purposes of determining any liability under the
Securities Act of 1933, the information omitted from the form of
prospectus filed as part of this registration statement in reliance
upon Rule 430A and contained in a form of prospectus filed by the
registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the
Securities Act shall be deemed to be part of the registration statement
as of the time it was declared effective.

(3) That, for the purpose of determining any liability under
the Securities Act of 1933, each post-effective amendment that contains
a form of prospectus shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide
offering thereof.

(4) Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing
provisions, or otherwise (other than pursuant to insurance), the
Registrant has been advised that in the opinion of the Commission such
indemnification is against public policy as expressed in the

II-3

Securities Act and may, therefore, be unenforceable. In the event that
a claim for indemnification against such liabilities (other than the
payment by the Registrant of expenses incurred or paid by a director,
officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding and other than insurance
payments) is asserted by such director, officer or controlling person
in connection with the securities being registered, the Registrant
will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the
final adjudication of such issue.

II-4

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets all
the requirements for filing on Form S-3 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Utica and the State of New York, on this 30th day of
April, 2002.

CONMED Corporation

By: /s/ Joseph J. Corasanti
-----------------------------------
Name: Joseph J. Corasanti
Title: President & Chief Operating Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Joseph J. Corasanti and Daniel S. Jonas, and each
of them, his true and lawful attorneys-in-fact and agents, with full power of
substitution and resubstitution, for him in his name, place and stead, in any
and all capacities, to sign any and all amendments (including post-effective
amendments) to this registration statement, and file the same, with all exhibits
thereto and other documents in connection therewith, with the Commission,
granting unto said attorneys-in-fact and agents, full power and authority to do
and perform each and every act and thing requisite and necessary to be done as
fully to all intents and purposes as he might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents or any of
them may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this
registration statement has been signed by the following persons in the
capacities indicated on April 30, 2002.

Signature Title
--------- -----

/s/ Eugene R. Corasanti Chairman of the Board
--------------------------- Chief Executive Officer and Director
Eugene R. Corasanti

/s/ Robert D. Shallish, Jr. Vice President-Finance
--------------------------- and Chief Financial Officer
Robert D. Shallish, Jr. (Principal Financial Officer)

/s/ Joseph J. Corasanti President, Chief Operating
--------------------------- Officer and Director
Joseph J. Corasanti

/s/ Luke A. Pomilio Vice President - Corporate Controller
--------------------------- (Principal Accounting Officer)
Luke A. Pomilio

/s/ Bruce F. Daniels Director
---------------------------
Bruce F. Daniels

II-5

Signature Title
--------- -----

/s/ Robert E. Remmell Director
---------------------------
Robert E. Remmell

/s/ William D. Matthews Director
---------------------------
William D. Matthews

/s/ Stuart J. Schwartz Director
-------------------------
Stuart J. Schwartz

II-6

NY12530:229547.7
EXHIBIT INDEX

Exhibit No. Description Location
----------- ----------- --------
1 Form of Underwriting Agreement between To be filed by Amendment.
the Company and the Underwriters
5.1 Opinion of Sullivan & Cromwell as to To be filed by Amendment.
the validity of the common stock
23.1 Consent of PricewaterhouseCoopers LLP Filed herewith.
23.2 Consent of Sullivan & Cromwell Included in Exhibit 5.1.
24.1 Powers of Attorney Included in signature
pages of this Registration
Statement.